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Abstract 
Hybrid PET/CT imaging is a newer cancer imaging modality which allows contemporaneous 
PET metabolic/molecular and CT anatomical imaging during a single diagnostic session on a 
single device. However, current PET imaging has relied heavily on measuring the tracer 
accumulation in the tumour as a surrogate of the pathologic activity targeted by the tracer while 
CT is limited to measuring tumour size or visualizing tumour enhancement pattern, all of which 
lack sensitivity and specificity in detecting cancer and assessing treatment response. Therefore, 
it is critical to develop pharmacokinetic techniques for assessing the physiologic/molecular 
characteristics of tumours with clinical PET/CT scanners to improve clinical decision made 
based on such imaging results. We hypothesized that quantitative pharmacokinetic and 
functional imaging using hybrid PET/CT could sensitively diagnose cancer and monitor its 
treatment response. My Ph.D. research focused on prostate and lung cancer. Patients with 
histologically confirmed cancer were evaluated using dynamic PET imaging with targeting 
tracers and CT Perfusion (CTP) with iodinated contrast agent to evaluate the metabolic and 
pathologic molecular activity and perfusion in tumours. 
In the lung cancer study, 26 patients with early-stage non-small cell lung cancer (NSCLC) 
were evaluated with dynamic [18F]FDG and CTP before and after neoadjuvant stereotactic 
ablative radiotherapy (SABR) to assess imaging response and the results correlated with 
pathological evaluation. The most sensitive model to predict pathological complete response 
combined BVpre-SABR (baseline blood volume) from CTP and relative change in SUVmax from 
PET to yield sensitivity, specificity, positive (PPV) and negative (NPV) predictive value and 
area under receiver operating characteristic curve (AUC) of 0.85, 0.92, 0.92, 0.86 and 0.92 
respectively. 
In the prostate cancer study, 23 and 19 patients were evaluated with dynamic [18F]FCH/CTP 
or [18F]DCFPyL/CTP, respectively. The most sensitive parameter set to localize and detect 
prostate cancer is Ki (plasma net uptake rate) and k4 (dissociation rate constant) of 
[18F]DCFPyL with sensitivity, specificity, PPV, NPV and AUC of 0.95, 0.92, 0.70, 0.98 and 
0.96 respectively with reference to the digital histopathological images. 
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In conclusion, our studies show that quantitative pharmacokinetic and functional parameters 
from dynamic PET and CTP can detect cancer and predict treatment response with acceptable 
performance metrics. 
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Summary of Lay Audience  
Hybrid positron emission tomography (PET)/computed tomography (CT) imaging is a newer 
cancer imaging modality which allows better diagnosis and monitoring of treatment response 
of cancer. PET uses small amounts of radioactive tracers to evaluate organ and tissue functions 
whereas CT create detail anatomical image of the body. Combining CT with PET as in a hybrid 
PET/CT scanner will lend form to function. 
However, current PET imaging is limited by subjective reading of images by experienced 
physicians while CT is limited to measuring tumour size or visualizing tumour shape. These 
qualitative features lack sensitivity and accuracy in detecting cancer and assessing treatment 
response. 
Therefore, it is critical to develop quantitative (objective vs. subjective) techniques to assess 
the physiologic and molecular characteristics of tumours from clinical PET/CT images to 
inform clinical decision.  
My Ph.D research focused on developing quantitative techniques to analyze prostate and lung 
cancer PET/CT images. In early-stage non-small cell lung cancer (NSCLC), PET images of 
glucose metabolism and CT blood volume images were able to predict cure of tumour as early 
as 8-week after stereotactic ablative radiotherapy (SABR). In prostate cancer, PET images of 
a tumour cell surface protein was very sensitive in identifying the most malignant tumour 
nodule so radiation can be concentrated on it to achieve a cure. 
In conclusion, my project shows that quantitative analysis of PET/CT images can detect cancer 
and predict treatment response better than current subjective (non-quantitative) reading of 
these images. 
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Preface 
 
 
 
 
 
 
 
 
“In the fields of observation chance favours only the prepared mind.” 
 – Louis Pasteur 
1 
 
Chapter 1  
1 Introduction 
Cancer is the number one cause of mortality in Canada. Canadian cancer statistics advisory 
committee estimates that 44% of Canadians (both males and females) will develop cancer 
in their lifetime, and 25% of Canadians will die of cancer (excluding Quebec) [1]. The 
number of cancer diagnosed cases each year has been increasing because of the growing 
age and ageing population. In 2019, the most commonly diagnosed cancers were lung, 
breast, colorectal and prostate cancers, accounting for nearly half (48%) of all cancers 
diagnosed.  
For diagnosis and treatment, the survival rate is significant because it indicates the 
effectiveness of cancer diagnosis and treatment. For all cancers combined, net five-year 
survival is 63%, and ten-year survival is 57%. The survival rate has been increased over 
time. Five-year survival in the early 1990s was 55% [1]. The abilities to have early cancer 
detection and accurate treatment guidance have been improving treatment outcomes and 
survival rates. 
Hybrid positron emission tomography (PET) and computed tomography (CT) is an 
advanced imaging modality which allows contemporaneous PET metabolic/molecular 
using tracers that target specific aberrant metabolic or molecular processes in the tumour 
and CT anatomical imaging with and/or without contrast during a single diagnostic session 
on a single device [2]. However, current cancer application of hybrid PET/CT imaging has 
relied heavily on either measuring the tracer accumulation (standardized uptake value 
(SUV)) in the tumour as a surrogate of the pathologic activity targeted by the tracer uptake 
or size measurement, all of which lacks sensitivity and specificity in detecting cancer and 
assessing response to treatment.  
Therefore, this Ph.D. dissertation focused on developing quantitative techniques for 
assessing the physiologic/molecular characteristics of tumours with clinical PET/CT 
scanners to improve clinical decisions made based on such imaging results. Based on the 
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availability of patient cohorts from existing clinical trials, lung cancer for monitoring 
treatment response and prostate cancer for cancer diagnosis were studied. 
1.1 Lung Cancer Epidemiology, Etiology and Prevention 
Lung cancer is the leading cause of cancer death, responsible for more cancer deaths among 
Canadians than the other three major cancer types (breast, colorectal and prostate cancers) 
combined. 1 in 15 Canadians is expecting to be diagnosed with lung cancer in their lifetime 
[1]. More than half of all lung cancer cases diagnosed in Canada are in the most advanced 
stage of the disease, and, as a result, its five-year and ten-year net survival rates are low – 
19% (95% confidence interval (CI), 18-19%) and 13% (95% CI, 13-13), respectively [3]. 
Lung cancer has high morbidity, high mortality and low survival rate; however, it also has 
the potential to prevent by eliminating tobacco use, reducing air pollution and exposure to 
radon and asbestos [4,5]. In fact, the lung cancer morbidity and mortality rate decreased 
with a reduction in the prevalence of daily smokers [1]. 
Lung cancer consists of two histological types, non-small cell lung cancer (NSCLC) and 
small cell lung cancer (SCLC), depends on the neuroendocrine features [6]. SCLC contains 
neuroendocrine features and comprises approximately 15% of all lung cancer [6,7]. 
NSCLC that comprises 85% of all lung cancer is classified further down into 
adenocarcinoma (mostly developed from peripheral lung tissue) or squamous-cell 
carcinoma (mostly developed centrally in the primary and secondary bronchi) if the 
morphologic evidence is clear [6,8-9]. If there is no clear morphologic evidence of 
adenocarcinoma or squamous-cell carcinoma, the tumour is classified as NSCLC not 
otherwise specified (NOS) [9]. The majority of lung cancer patients develop 
adenocarcinoma [10]. Although it is associated with tobacco use, it is also the most 
common type of lung cancer among non-smokers [10,11]. 
The majority of patients with lung cancer present with advanced stages of the disease 
because lung cancer may not cause any symptoms in its early stages. Some symptoms do 
not appear until cancer has metastasized to other parts of the body. Typical signs and 
symptoms of lung cancer that the patients present are cough, dyspnea (shortness of breath), 
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chest pain, hemoptysis (coughing up of blood) and weight loss [8,11]. These signs and 
symptoms are not specific to lung cancer. Other pulmonary diseases, including chronic 
obstructive pulmonary disease (COPD), have similar symptoms. Therefore, cancer 
screening is crucial to prevent lung cancer, especially for patients with a history of chronic 
cough with or without hemoptysis in a current or former smoker with COPD age 40 years 
or older [11]. 
1.2 Lung Cancer Screening, Diagnosis and Staging 
By the time the patients diagnosed with lung cancer, the disease is advanced because the 
signs and symptoms of early-stage lung cancer are non-specific and may not cause any 
symptoms. The overall five-year survival is only 19% [3]. In the United States, the 
mortality rate of breast cancer has steadily decreased since 1989 [12], and a majority of 
breast cancer is diagnosed as stage I [13] due to comprehensive mammography screening 
for American women. Therefore, screening and early detection of cancer at a more treatable 
stage is a prudent goal without a doubt. 
The National Lung Screening Trial (NLST) started in 2002 was a game-changer in the lung 
cancer screening paradigm with low-dose CT. Screening with chest X-ray and sputum 
cytology that were a standard of care before NLST did not show a decrease in lung cancer 
mortality in all four different studies [14-17]. NLST – the multicentre randomized 
controlled trial – enrolled 53,456 current and former cigarette smokers who were between 
55 and 74 years old with a required smoking history of a minimum of 30 pack-years for 
current smokers and smoking cessation within the past 15 years [18]. 
NLST results showed a relative reduction in mortality from lung cancer with low-dose CT 
screening of 20.0% (95% CI, 6.8-26.7; P=0.004) and the all-cause mortality was reduced 
in the low-dose CT group, as compared with the radiography group, by 6.7% (95% CI, 1.2-
13.6; P=0.02) [19,20]. The lung cancer screening paradigm with low-dose CT improved in 
the Nederlands-Leuvens Longkanker Screenings Onderzoek (NELSON) trial by using a 
two-step process during the interpretation of the patient’s nodule size. Lung nodules >10 
mm were positive; those <5 mm were negative, and those ranging between 5 and 10 mm 
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were indeterminate and underwent a follow-up CT scan. The NELSON trial achieved a 
sensitivity of 94.6% (95% CI, 86.5-98.0), a specificity of 98.3% (95% CI, 98.0-98.6), a 
positive predictive value of 35.7% (95% CI, 29.3-42.7, and negative predictive values of 
99.9% (95% CI, 99.9-100.0) [21]. Low-dose CT is a cost-effective, noninvasive, highly 
sensitive and specific test for lung cancer [22]. Annual screenings of high-risk patients 
using low-dose CT are an effective way to diagnose lung cancer early and reduce the high 
mortality rates associated with lung cancer [22]. Further specific imaging tests, such as 
magnetic resonance imaging (MRI), CT and PET, are prepared and performed if suspicious 
lung nodule is detected; furthermore, a biopsy, such as a bronchoscopy, mediastinoscopy 
and needle can determine if the tissue is cancerous.  
After a diagnosis, the stage of lung cancer describes the progression or extent of lung 
cancer. SCLC is categorized into two stages, called limited-stage and extensive-stage [23]. 
The limited-stage is confined to one hemithorax, although local extension and neighbouring 
lymph nodes could also be present. The extensive-stage involves both hemithorax and other 
parts of the body. NSCLC is categorized by tumour-node-metastasis (TNM)-based 
classification of lung cancer by the eighth edition of the lung cancer stage classification 
[24]. Table 1.1 shows tumour (T), node (N), metastasis (M) descriptors based on the size 
of the primary tumour, lymph node involvement and distant metastasis. There are four 
main stages (I, II, III and IV) [24]. Stage I is the earliest stage of the disease and have a 
better prognosis than later stages. Stage IV is the most advanced stage of the disease. Table 
1.2 shows lung cancer stage grouping by TNM classification. 
 
Table 1.1: TNM Classification System for Lung Cancer 
T (Primary Tumour) Label 
T0 No primary tumour 
Carcinoma in situ (Squamous or Adenocarcinoma) 
 
Tis 
T1 Tumour ≤3 cm, 
Minimally invasive adenocarcinoma 
Superficial spreading tumour in central airways† 
Tumour ≤ 1 cm 
Tumour >1 but ≤2 cm 
Tumour >2 but ≤3 cm 
 
T1a(mi) 
T1aSS 
T1a≤1 
T1b>1-2 
T1c>2-3 
5 
 
T2 Tumour >3 but ≤5 cm or tumour involving: 
     Visceral pleura††, 
     Main bronchus (not carina), atelectasis to hilum†† 
Tumour >3 but ≤4 cm 
Tumour >4 but ≤5 cm 
 
T2Visc Pl 
T2Centr 
T2a>3-4 
T2b>4-5 
T3 Tumour >5 but ≤7 cm 
or invading chest wall, pericardium, phrenic nerve 
or separate tumour nodule(s) in the same lobe 
T3>5-7 
T3Inv 
T3Satell 
T4 Tumour >7 cm  
or tumour invading mediastinum, diaphragm, heart, great vessels, 
     recurrent laryngeal nerve, carina, trachea, esophagus, spine 
or tumour nodule(s) in a different ipsilateral lobe 
T4>7 
T4Inv 
 
T4Ipsi Nod 
TX T status not able to be assessed  
N (Regional Lymph Nodes)  
N0 No regional node metastasis  
N1 Metastasis in ipsilateral pulmonary or hilar nodes  
N2 Metastasis in ipsilateral mediastinal/subcarinal nodes  
N3 Metastasis in contralateral mediastinal/hilar, or supraclavicular nodes  
NX N status not able to be assessed  
M (Distant Metastasis)  
M0 No distant metastasis  
M1a 
Malignant pleural/pericardial effusion††† or pleural/pericardial nodules 
or separate tumour nodule(s) in a contralateral lobe 
M1aPl Dissem 
M1aContr Nod 
M1b Single extrathoracic metastasis M1bSingle 
M1c Multiple extrathoracic metastases (1 or more organ) M1cMulti 
Abbreviations: T – Tumour; N – Node; M – Metastasis; †Superficial spreading tumour of 
any size but confined to the tracheal or bronchial wall; ††such tumours are classified as 
T2a if >3 but ≤4 cm, T2b if >4 but ≤5 cm; †††Pleural effusions are excluded that are 
cytologically negative, non-bloody, transudative, and clinically judged not to be due to 
cancer. 
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Table 1.2: Lung Cancer Stage Groups 
Stage T N M 
Stage IA1 T1a N0 M0 
Stage IA2 T1b N0 M0 
Stage IA3 T1c N0 M0 
Stage IB T2a N0 M0 
Stage IIA T2b N0 M0 
Stage IIB T1-T2 N1 M0 
 T3 N0 M0 
Stage IIIA T1-T2 N2 M0 
 T3 N1 M0 
 T4 N0-N1 M0 
Stage IIIB T1-T2 N3 M0 
 T3-T4 N2 M0 
Stage IIIC T3-T4 N3 M0 
Stage IVA Any T Any N M1a/M1b 
Stage IVB Any T Any N M1c 
Abbreviations: T – Tumour; N – Node; M – Metastasis. 
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1.3 Lung Cancer Treatment 
Treatment options include surgery, radiation therapy and/or chemotherapy depending on 
the stage of the lung cancer, patient’s health and the function of the lung. For SCLC, the 
limited-stage is typically treated with a combination of chemotherapy and radiation 
therapy, whereas the extensive-stage is treated with systemic chemotherapy [25]. 
Surgical resection is the standard of care for the treatment of stage I and II NSCLC [26,27]. 
Different surgical approaches, including lobectomy (removal of a lobe of the lung), 
segmentectomy (removal of a part of the lobe) and wedge resection (removal of a smaller 
part of the lobe than segmentectomy) are recommended based on the patients’ condition. 
Nonsurgical approaches, such as stereotactic ablative radiation therapy (SABR) is 
suggested for high-risk or medically inoperable patients with stage I NSCLC who cannot 
tolerate a surgical resection [26,27]. Evidence showed that SABR provides greater local 
control than standard radiation therapy for inoperable patients with stage I NSCLC [28,29]. 
For stage II NSCLC, the use of adjuvant chemotherapy is recommended [26,30]. A 
combination of surgery, radiation therapy and/or chemotherapy is the recommended 
approach for stage III NSCLC [30,31]. Multimodality therapy is preferable than a single 
type of therapy alone in patients with stage III lung cancer [30,31]. Patients with stage IV 
NSCLC is considered palliative (treatable but not curable) and may retain a good 
performance status by taking chemotherapy and/or epidermal growth factor receptor-
targeted therapy [30,32,33].  
It stands to reason that the survival rate decreased as the disease advanced. Table 1.3 shows 
the overall five-year clinical (before initiation of any treatment) and pathologic (after 
resection) survival rates reported by the International Association for the Study of Lung 
Cancer, analyzing lung cancer patients worldwide between 1999 and 2010 [34]. 
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Table 1.3: Five-year Survival (%) of Lung Cancer 
Stage IA1 IA2 IA3 IB IIA IIB IIIA IIIB IIIC IVA IVB 
Clinical 92 83 77 68 60 53 36 26 13 10 0 
Pathologic 90 85 80 73 65 56 41 24 12 - - 
 
 Surgical Resection for Early Stage NSCLC 
Surgical resection is the standard of care for medically operable early-stage (T1T2N0) 
NSCLC; especially lobectomy is the gold standard. Patients who are unfit for a full 
lobectomy, segmentectomy or wedge resection is considered to preserve pulmonary 
function, mainly force expiratory volume in one second [35,36]. However, a randomized 
control trial in 1995 comparing lobectomy vs. limited resection (segmentectomy and 
wedge resection) did not recommend segmentectomy and wedge resection as a standard of 
care because of reduced survival and increased risk of locoregional recurrence rate [37].  
Video-assisted thoracoscopic surgery lobectomy that is newly developed with advancing 
in intervention technology uses a minimally invasive approach. It demonstrated similar 5-
year survival but with less postoperative pain and a better quality of life [38,39]. The local 
control for the video-assisted thoracoscopic surgery lobectomy in early-stage NSCLC was 
ranged from 88-100% [40]. 
 Stereotactic Ablative Radiation Therapy for Early Stage 
NSCLC 
SABR also referred to as stereotactic body radiation therapy (SBRT), is a guideline-
recommended treatment option for early-stage (T1T2N0) NSCLC patients who decline 
surgery or are high-risk or medically inoperable patients. SABR was first introduced in 
2003 and its use has been increasing exponentially [27,41]. SABR delivers a high dose of 
radiation in a small number of fractions (7.5-18 Gy per fraction) over 1-2 weeks, whereas 
conventional radiation therapy delivers 2 Gy per fraction over 4-6 weeks [29,42]. This 
hypofractionated stereotactic regimen radiation therapy, SABR, is integrated with a 
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sophisticated planning system that able to generate highly conformal plans with precise 
dose planning, targeting and radiation delivery [43]. 
The local control for SABR provides greater local control than standard radiation therapy 
for inoperable patients with early-stage NSCLC [28,29]. The reported three-year local 
control often exceeds 90% with maintaining biological effective dose (assuming α/β ratio 
of 10) of at least 100 Gy10 [44]. Two independent phase III randomized studies – STARS 
from the United States and ROSEL from the Netherlands – assessed overall survival for 
SABR vs. lobectomy. Pooled analysis showed that estimated overall survival at three years 
was 95% (95% CI, 85-100) in the SABR group and 79% (95% CI, 64-97%) in the 
lobectomy group (P=0.037) [45]. Local recurrence-free at three-year was 96% (95% CI, 
89-100) in the SABR group and 100% (95% CI, 100-100% in the lobectomy group 
(P=0.32). Regional nodal recurrence-free at three-year was 90% (95% CI, 80-100) in the 
SABR group and 96% (95% CI, 80-100% in the lobectomy group (P=0.32). Recurrence-
free survival at three years was 86% (95% CI, 74-100) in the SABR group and 80% (95% 
CI, 65-97) in the lobectomy group (P=0.54) [45]. These results showed that SABR could 
be considered as an option for the treatment of operable early-stage NSCLC; however, 
additional more extensive randomized studies are required to justify fully. 
1.4 Monitoring Lung Cancer Treatment Response 
Current clinical guidelines to evaluate treatment response for NSCLC are Response 
Evaluation Criteria in Solid Tumours (RECIST) version 1.1 [46] and PET Response 
Criteria in Solid Tumours (PERCIST) version 1.0 [47]. RECIST is based on anatomical 
measurement of tumour size using CT, MRI or chest X-ray. PERCIST is based on the tracer 
accumulation of [18F]fluodeoxyglucose (FDG) in tumour using PET. 
 Response Evaluation Criteria in Solid Tumours (RECIST) 
RECIST was first introduced in 2000 [48], and was updated to version 1.1 in 2009. The 
guideline describes an approach to measure solid tumour and defines an objective 
assessment of change in anatomic tumour size for clinical trials. For NSCLC, chest CT is 
the preferred modality over chest X-ray and any other modalities, and the scan is assumed 
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to have a CT slice thickness of ≤5 mm. There are four response criteria: Complete Response 
(CR), Partial Response (PR), Progressive Disease (PD) and Stable Disease (SD). When 
more than one measurable lesion is present at baseline, all lesions up to a maximum of five 
lesions total (and a maximum of two lesions per organ) representative of all involved 
organs should be identified as target lesions. Table 1.4 shows the response criteria of 
RECIST 1.1 
 
Table 1.4: Response Criteria of RECIST 1.1 
Evaluation of target lesions 
CR 
Disappearance of all target lesions. Any pathological lymph nodes 
(whether target or non-target) must have a reduction in short axis to 
<10 mm. 
PR 
At least a 30% decrease in the sum of diameters of target lesions, taking 
as reference the baseline sum diameters. 
PD 
At least a 20% increase in the sum of diameters of target lesions, taking 
as reference the smallest sum on study (this includes the baseline sum if 
that is the smallest on study). In addition to the relative increase of 20%, 
the sum must also demonstrate an absolute increase of at least 5 mm. 
SD 
Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD, taking as reference the smallest sum diameters while on 
study. 
Evaluation of non-target lesions 
CR 
Disappearance of all non-target lesions and normalisation of tumour 
marker level. All lymph nodes must be non-pathological in size (<10 mm 
short axis) 
Non-CR/Non-PD 
Persistence of one or more non-target lesion(s) and/or maintenance of 
tumour marker level above the normal limits. 
PD 
Appearance of one or more new lesions and/or unequivocal progression 
of existing non-target lesions. 
Abbreviations: CR – Complete Response; PR – Partial Response; PD – Progressive 
Disease; SD – Stable Disease. 
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 PET Response Criteria in Solid Tumours (PERCIST) 
PERCIST 1.0 was introduced in 2009. This guideline describes an approach to measure 
the metabolic tumour response assessment with [18F]FDG PET. RECIST covers only 
anatomical imaging; however, the biologic predictive value of [18F]FDG PET appears to 
be greater than anatomic measurements in some cancers, including NSCLC [47]. Similar 
to RECIST, PERCIST determines a maximum of five lesions total (and a maximum of two 
lesions per organ), but with the most intense [18F]FDG uptake. The metric that PERCIST 
uses is the peak intensity image-derived radioactivity concentration (uptake) normalized to 
lean body mass (SULpeak) of lesions. SUV is the uptake normalized by total body mass. 
Table 1.5 shows the response criteria of PERCIST 1.0 
 
Table 1.5: Response Criteria of PERCIST 1.0 
Objective Response 
CMR 
• Complete resolution of [18F]FDG uptake within measurable target 
lesion so that it is less than mean liver activity and indistinguishable 
from surrounding background blood-pool levels. 
• Disappearance of all other lesions to background blood-pool levels. 
• No new [18F]FDG-avid lesions in pattern typical of cancer.  
• If progression by RECIST, must verify with follow-up. 
PMR 
• Reduction of minimum of 30% in target measurable tumour [18F]FDG 
SULpeak. Absolute drop in SUL must be at least 0.8 SUL units, as well.  
• No increase >30% in SUL or size of target or non-target lesions. 
• No new lesions. 
PMD 
• >30% increase in [18F]FDG SULpeak, with >0.8 SUL unit increase in 
tumour SUVpeak from baseline scan in pattern typical of tumour and 
not of infection/treatment effect. 
• Visible increase in the extent of [18F]FDG tumour uptake. 
• New [18F]FDG-avid lesions that are typical of cancer and not related 
to treatment effect or infection. 
SMD Not CMR, PMR, or PMD 
Abbreviations: CMR – Complete Metabolic Response; PMR – Partial Metabolic 
Response; PMD – Progressive Metabolic Disease; SMD – Stable Metabolic Disease; 
[18F]FDG – Fluorine 18 labelled fluorodeoxyglucose; RECIST – Response Evaluation 
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Criteria in Solid Tumours; SUL - Image-derived radioactivity concentration (uptake) 
normalized to lean body mass. 
 
 Radiation-Induced Lung Injury (RILI) 
Despite the promising results reported with SABR, the concordance of tumour responses 
between morphologic and metabolic criteria using RECIST and PERCIST lacks sensitivity 
and specificity. Radiation-induced lung injury (RILI), that occur in the acute phase (within 
6 months) as radiation pneumonitis and in the late phase (after 6 months) as fibrosis, 
manifests on CT after SABR in most patients and impairs the measurement of patients’ 
tumour response to treatment [42,49]; moreover, a high [18F]FDG SUV, as a surrogate of 
hypermetabolic activity, was observed in RILI due to the inflammatory response following 
SABR [50]. Because RILI shows the similar anatomical size, morphology and [18F]FDG 
uptake to a recurrent tumour following treatment with SABR [51,52], it would be hard to 
distinguish between RILI and recurrence after SABR for NSCLC with RECIST and 
PERCIST. 
 Other Imaging Modalities to Distinguish between RILI and 
Recurrence 
Radiomics is the mining of quantitative image features from standard-of-care medical 
imaging [53]. The use of radiomics in oncology, and specifically radiation oncology, has 
been rapidly expanding to quantify tumour heterogeneity and predict response [54]. After 
images are acquired, a region of interest (ROI) is segmented to determine which voxels 
within an image are analyzed. ROIs are characterized according to extracted quantitative 
image features, including first-order statistics (e.g. mean, median and standard deviation) 
and second-order texture features [55]. Then the extracted features are selected from a 
dataset by different machine learning (supervised or unsupervised) models, such as support 
vector machines, Bayesian networks, neural networks, and more. The model performance 
is assessed to validate and reported in terms of the area under the receiving operating 
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characteristic (ROC) curve (AUC). The AUC for distinguishing RILI and recurrence in 
NSCLC after SABR using radiomics on post-SABR CT imaging was 0.65-0.80 [56-57].  
All these assessment tools, including RECIST, PERCIST and radiomics, have relied 
heavily on static measurement that is either measuring the tracer uptake/accumulation 
(SUV) in the tumour as a surrogate of the pathologic activity targeted by the tracer or 
tumour morphology. Functional imaging, such as CT Perfusion, dynamic contrast-
enhanced (DCE)-MRI, dynamic PET would give additional information about the tissues. 
Dynamic PET with appropriate tracers and CT Perfusion and DCE-MRI with a contrast 
agent to evaluate the metabolic and pathologic molecular activity and perfusion in tissues. 
Tumour pathophysiologic parameters including perfusion, blood volume, vessel 
permeability surface product and glucose metabolic rate could be more sensitive to SABR 
than either RECIST or PERCIST. Evidence showed that the tumour vascularization 
significantly reduced in advanced NSCLC in chemotherapy [58,59], and ROC analysis 
showed AUC of 0.78-0.87 [59]. Therefore, measuring tumour vasculature is a potential 
biomarker to monitor other treatment options. Studies presented in Chapters 2 and 3 were 
the first study to assess the utility of quantitative functional imaging for assessing tumour 
response after SABR in lung cancer. 
1.5 Prostate Cancer Epidemiology, Etiology and Prevention 
Prostate cancer is the most commonly diagnosed cancer among Canadian men. 1 in 9 
Canadian men is expecting to be diagnosed with prostate cancer in their lifetime [1]. Most 
men diagnosed with prostate cancer are over the age of fifty. Unlike lung cancer, five-year 
and ten-year net survival rates are high – 93% (95% CI, 92–93) and 90% (95% CI, 89-90), 
respectively [3]. Prostate cancer has high morbidity, high mortality and low preventability; 
however, it has high survival rates. The prostate cancer mortality rate has been declined by 
-2.8% annually since 1994 with improved treatments, including advances in radiation 
therapy [1,60]. 
Prostate cancer consists of many histological subtypes, including adenocarcinomas, small 
cell carcinomas, neuroendocrine tumours, transitional cell carcinomas, sarcomas and rare 
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usual subtypes [61,62]. Almost all prostate cancer patients develop adenocarcinoma. 
Typical signs and symptoms arising from prostate cancer are bladder outlet obstruction, 
including urinary hesitancy (trouble starting or maintaining a urine stream), nocturia (urge 
to urinate frequently at night), incomplete emptying and a diminished urinary stream [62]. 
These signs and symptoms are not specific to prostate cancer. They are more commonly 
appear in benign prostatic hyperplasia (enlargement of the prostate), which can be 
differentiated by a careful digital rectal exam (DRE) and a prostate-specific antigen (PSA) 
test. The acute development of pelvic or perineal pain, erectile dysfunction, hematuria 
(blood in the urine), unexplained weight loss or fatigue should prompt further evaluation 
of the prostate [62]. 
Also, there have been some indications that the Western diet, especially high in meat and 
high-fat dairy, increases the risk of prostate cancer. [63,64]. Therefore, it is reasonable to 
recommend a low-fat diet and regular exercise to prevent prostate cancer. 
1.6 Prostate Cancer Screening, Diagnosis and Staging 
About 3 in 4 prostate cancer in Canada were diagnosed at early-stage (22.5% at stage I and 
51.9% at stage II) [65], which also explains why the survival rate is high in prostate cancer. 
The advent of PSA testing with or without DRE screening increased the detection of 
prostate cancer at early-stage. DRE is an exam in which the physician inserts a finger into 
the rectum and palpates the prostate gland to determine whether any abnormal enlargement 
of the gland is present. The PSA test is a test that measures the level of PSA in a man’s 
blood. PSA is a protein produced by epithelial cells of the prostate gland. Besides cancer, 
PSA levels can be raised by benign prostatic hyperplasia, asymptomatic inflammation, 
prostatitis (infected prostate), or simply just by ageing. However, it is unclear that the role 
that screening with the PSA test played is reducing the mortality rate studied by two 
multicentre randomized controlled trials (PLCO and ERSPC trial) [66-68]. Based on the 
current evidence, the Canadian Task Force on Preventive Health Care recommends not 
screening for prostate cancer with the PSA test [69].  
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If a patient has a PSA level of greater than 4.0 ng/mL, physicians would recommend a 
prostate biopsy to determine whether prostate cancer is present. Trans-rectal ultrasound 
(TRUS)- and MRI-guided biopsy are the two primary guided biopsy method for prostate 
cancer. TRUS- and/or multiparametric MRI (mpMRI)-guided biopsy use imaging 
guidance and a needle to remove tissue to examine for disease in the prostate, and mpMRI 
showed superior clinical assessment to TRUS [70,71]. 
After the presence of prostate cancer is confirmed by biopsy, the stage of prostate cancer 
is measured. Prostate cancer stage grouping is determined by TNM, PSA level and Gleason 
group-based classification of prostate cancer by the eighth edition of the prostate cancer 
state classification [72]. Table 1.6 shows TNM, PSA level and Gleason group descriptors. 
TNM is based on the tumour involvement, lymph node involvement and distant metastasis. 
PSA level is based on the measured PSA in blood reported as nanogram of PSA per 
millilitre (ng/mL). Gleason group is based on the Gleason score that is the histologic pattern 
of arrangement of carcinoma cells in hematoxylin and eosin (H&E) stain ranges from 1 to 
5, 1 as tissue with a small sign of cancer and 5 as a tissue with the most aggressive sign of 
cancer. There are four main stages (I, II, III and IV) [72]. Stage I is the earliest stage of the 
disease and have a better prognosis than later stages. Stage IV is the most advanced stage 
of the disease. Table 1.7 shows lung cancer stage grouping by TNM classification 
 
Table 1.6: TNM, PSA Level and Gleason Group Classification System for Prostate 
Cancer 
cT (Clinical T of Primary Tumour) Label 
T0 No evidence of primary tumour  
T1 Clinically inapparent tumour that is not palpable 
     Tumour incidental histologic finding in 5% or less of tissue resected 
     Tumour incidental histologic finding in more than 5% of tissue 
     resected 
     Tumour incidental by needle biopsy found in one or both sides, but 
     not palpable 
 
T1a 
T1b 
 
T1c 
 
T2 Tumour is palpable and confined within prostate 
     Tumour involves one-half of one side or less 
 
T2a 
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     Tumour involves more than one-half of one side but not both sides 
     Tumour involves both sides 
T2b 
T2c 
T3 Extraprostatic tumour that is not fixed or does not invade adjacent 
structures 
     Extraprostatic extension (unilateral or bilateral) 
     Tumour invades seminal vesicles 
 
 
T3a 
T3b 
T4 
Tumour is fixed or invades adjacent structures other than seminal 
vesicles such as external sphincter, rectum, bladder, levator muscles, 
and/or pelvic wall 
 
TX Primary tumour cannot be assessed  
pT (Pathological T)  
T2 Organ confined  
T3 Extraprostatic extension 
     Extraprostatic extension (unilateral or bilateral) or microscopic 
     invasion of bladder neck 
     Tumour invades seminal vesicle(s) 
 
T3a 
 
T3b 
T4 
Tumour is fixed or invades adjacent structures other than seminal 
vesicles such as external sphincter, rectum, bladder, levator muscles, 
and/or pelvic wall 
 
N (Regional Lymph Nodes)  
N0 No positive regional nodes  
N1 Metastases in regional node(s)  
NX Regional nodes were not assessed  
M (Distant Metastasis)  
M0 No distant metastasis  
M1 Distant metastasis 
     Nonregional lymph nodes metastasis 
     Distant bone(s) metastasis 
     Other site(s) with or without bone disease 
 
M1a 
M1b 
M1c 
PSA (Prostate-Specific Antigen, ng/mL)  
PSA 
value 
<10 
≥10<20 
<20 
≥20 
Any value 
 
G (Histologic Grade Group)  
1 Gleason Score ≤ 3+3  
2 Gleason Score 3+4  
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3 Gleason Score 4+3  
4 Gleason Score 4+4  
5 Gleason Score 4+5, 5+4, or 5+5  
Abbreviations: T – Tumour; N – Node; M – Metastasis; PSA – Prostate-specific antigen; 
G – Gleason group. 
 
Table 1.7: Prostate Cancer Stage Groups 
Stage T N M PSA G 
Stage I cT1a-c, cT2a N0 M0 < 10 1 
 pT2 N0 M0 < 10  1 
Stage IIA cT1a-c, cT2a N0 M0 ≥10<20 1 
 cT2b-c N0 M0 <20 1 
Stage IIB T1-2 N0 M0 <20 2 
Stage IIC T1-2 N0 M0 <20 3 
 T1-2 N0 M0 <20 4 
Stage IIIA T1-2 N0 M0 ≥20 1-4 
Stage IIIB T3-4 N0 M0 Any 1-4 
Stage IIIC Any T N0 M0 Any 5 
Stage IVA Any T N1 M0 Any Any 
Stage IVB Any T N0 M1 Any Any 
Abbreviations: T – Tumour; N – Node; M – Metastasis; PSA – Prostate-specific antigen; 
G – Gleason group. 
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1.7 Prostate Cancer Diagnosis with Different Imaging 
Modalities 
 Computed Tomography (CT) 
The conventional CT is not used for the detection and staging of primary prostate cancer 
because of the poor contrast between different soft tissues within the prostate. The use of 
conventional CT is limited to distant staging, radiation therapy treatment planning and 
PET/CT for prostate cancer. CT images are useful for attenuation correction and scatter 
correction to improve the quality of PET images. Also, it gives the anatomical references 
when co-registered with PET images [73]. 
 Multiparametric MRI (mpMRI) 
Multiparametric MRI (mpMRI) for prostate cancer is a novel promising imaging modality 
for diagnosis and uses a combination of parametric MRI techniques. The techniques 
include five sequences: T1-weighted images, T2-weighted images, diffusion-weighted 
images (DWI), dynamic contrast-enhanced (DCE) images and magnetic resonance 
spectroscopy (MRS) images [74]. T1-weighted imaging is used mainly for the evaluation 
of regional lymph nodes and bone structures [75]. T2-weighted imaging is a fundamental 
sequence in mpMRI of the prostate, providing a highly defined anatomical image of the 
zonal architecture of the prostate gland with excellent soft-tissue contrast [76]. DWI 
quantifies the diffusion of water molecules within tissues [77]. DCE images can analyze 
the microvascular properties of tissues based on the evaluation of differences in the 
velocities and intensities of contrast agent uptake and washout by malignant and non-
malignant prostatic tissue [78]. MRS sequences visualize the pattern of expression of 
specific metabolites, such as citrate and choline [79]. 
An advantage of using mpMRI is the standardized imaging-derived scoring systems to 
interpret and report to provide acceptable accuracy in detecting prostate cancer using 
mpMRI. The Prostate Imaging - Reporting and Data System (PI-RADS) was first 
introduced in 2005 to standardization and diminish variation in the acquisition, 
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interpretation, and reporting of prostate mpMRI examination [75]. PI-RADS has been 
updated to version 2.1 since 2019 [80]. PI-RADS uses a five-point scale (PI-RADS 1 as 
very low (clinically significant cancer is highly unlikely to be present) to PI-RADS 5 as 
very high (clinically significant cancer is highly likely to be present)). Multiple studies 
showed that the sensitivity and specificity of PI-RADS v2 were 0.86-1.00 and 0.50-0.83, 
respectively [81-83].  
 Positron Emission Tomography (PET)/CT 
PET/CT imaging is an imaging technique for the acquisition of both metabolic and 
anatomical imaging data using a single device in a single diagnostic session. The most 
commonly used PET tracer in oncology is [18F]FDG, as a glucose analog, that measures 
glucose transport and metabolism. Increased glucose metabolism in cancer cells by 
anaerobic glycolysis that is called the Warburg effect is observed and used as a biomarker 
for malignancy [84]. When FDG enters a cell, it is phosphorylated into FDG-6-phosphate 
by hexokinase, which designed to irreversibly bound to cells. 
FDG is also known to accumulate in benign hyperplasia, post-treatment change and 
inflammatory process [85]. For example, higher FDG uptake is observed in prostatitis and 
benign prostatic intraepithelial hyperplasia than normal tissue. FDG also accumulate in the 
urinary bladder via urinary excretion. Because of low tumour-to-background signal and 
urinary excretion, [18F]FDG PET has been found to have low sensitivity and specificity for 
the assessment of prostate cancer [86,87]. Therefore, it is not recommended for diagnosing 
prostate cancer. 
PET is also capable of using different tracers/radioligands that target different molecular 
pathways. [11C] or [18F] labelled choline tracer, such as [18F]fluorocholine (FCH), is used 
for imaging phosphorylation of choline which is responsible for the synthesis of the 
phospholipid production. Choline kinase is the enzyme that catalyzed the phosphorylation 
of choline through the Kennedy pathway (first half of the CDP-choline pathway) which 
describes the de-novo synthesis of phosphatidylethanolamine and phosphatidylcholine 
[88,89]. Overexpression of choline kinase has been found in prostate cancer [90,91]. It was 
suggested that the choline metabolic pathway is a promising imaging target [90,92]. 
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However, previous clinical studies had shown that the differentiation of benign tissue from 
malignant tumour tissue was not possible with FCH PET imaging, and not recommended 
for localizing primary prostate cancer [93,94] unless multiple TRUS-guided biopsies with 
negative findings in highly selected patients could be helpful and contribute valuable 
additional information regarding the detection of the primary tumour [94]. 
Prostate-specific membrane antigen (PSMA), a type II integral membrane protein, has 
received huge attention. PSMA is a highly promising biomarker for targeted prostate 
cancer because of its overexpression of 100- to 1000-fold in prostate cancer compared to 
benign prostate tissue. Several PSMA-ligand has been developed and labelled with 
positron emitters [95]. Among these small-molecule PSMA-imaging agents, especially 
68Ga-labelled, such as 68Ga-PSMAHBED-CC have been introduced into clinical 
applications for PSMA imaging in prostate cancer patients [96,97]. So far, previous studies, 
mainly retrospective, demonstrate a higher diagnostic efficacy of 68Ga-PSMA ligand PET 
imaging compared to FCH imaging [98-103]. [18F]labeled PSMA ligand, such as 2-(3-{1-
carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic 
acid, commonly known as [18F]DCFPyL provided a high image quality and visualized 
small prostate lesions with excellent sensitivity [104]. Comparing both 68Ga-PSMAHBED-
CC to [18F]DCFPyL, all suspicious lesions identified with 68Ga-PSMAHBED-CC were 
detected with [18F]DCFPyL [105]. The sensitivity of PSMA-ligand PET was reported from 
64% (95% CI, 56-72) to 80% (95% CI, 66-89), and the specificity was reported from 94% 
(95% CI, 86-98) to 97% (95% CI, 92-99) [99,106], which lack sensitivity. There is room 
to improve diagnostic performance. Studies presented in Chapters 4 and 5 showed a 
sensitive method to detect and localize a cancer nodule within the prostate, especially 
dominant intraprostatic lesion (DIL) using dynamic [18F]FCH PET/CTP or dynamic 
[18F]DCFPyL PET/CTP imaging. 
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1.8 Quantitative Functional Imaging 
 Kinetic Modeling for Dynamic PET and CT Perfusion 
The amount of blood-born tracer/solute ([18F]FDG, [18F]FCH and [18F]DCFPyL for 
dynamic PET and CT iodinated contrast agent for CTP for this study) accumulated in a 
tumour at any time after injection into the circulation is the balance of several processes: 
(a) delivery of tracer to the tumour site by perfusion; (b) bidirectional exchange (influx and 
efflux) of the tracer between vessels and the tumour interstitium; (c) binding and 
disassociation of the tracer from its target. Process (c) only applies to PET tracers 
[18F]FDG, [18F]FCH and [18F]DCFPyL as CT contrast agent is inert and does not bind to 
any known targets in the tumour. Different physiologic/molecular parameters can 
characterize each of these processes: (a) perfusion, (b) flow extraction product and 
backflux rate constant and (c) binding and dissociation rate constant.  
All these parameters singly or in combination can increase the sensitivity and specificity 
of dynamic PET and CTP in detecting cancer and monitoring treatment response. The 
multitude of processes involved in the uptake of tracer means that PET SUV which 
measures the uptake of a tracer at one time can lead to a misleading interpretation of tumour 
activity. At early times following injection, tracer uptake/SUV is dominated by perfusion 
while at later times by binding and dissociation from the target. For example, the higher 
uptake at early times may not signify hypermetabolic activity as much as higher perfusion. 
Therefore, SUV is not the appropriate methodology, and tracer kinetic modeling that 
accounts for different processes is required.  
Johnson-Wilson-Lee (JWL) model [107] describes the transport of tracer via blood flow 
into the tissue/tumour site and subsequent leakage into the interstitial space. On the other 
hand, the standard closed 2-tissue compartment model (S2TCM) [108] used to describe the 
binding to targets only models the exchange of the tracer between vessels and the tumour 
interstitial space and the binding and dissociation from the target while tracer delivery by 
blood flow (perfusion) to the vessels in a tumour is completely ignored.  
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To remedy this omission of the blood flow effect, JWL and S2TCM were combined to 
arrive at the hybrid model called the flow-modified 2-tissue compartment model (F2TCM) 
shown in figure 1.1 to analyze the dynamic PET data. In figure 1.1, F (mL·min-1·g-1) is the 
blood flow to the tissue voxel, Vb (mL·g
-1) is the voxel blood volume; K1 (mL·min
-1·mL-
1) is the influx rate constant of tracer into the tissue and k2 (min
-1) is the efflux rate constant 
from tissue into blood vessels; k3 (min
-1) is the binding rate constant to and k4 (min
-1) is the 
dissociation rate constant from the target. CA(t), CV(t) and CE(t) are concentrations of free 
tracer in arterial and venous blood and tissue; and, CM(t) is a concentration of bound tracer. 
 
 
Figure 1.1: F2TCM, a hybrid kinetic model incorporating the JWL model and S2TCM to 
describe the measured tissue time-activity curve.  
Abbreviations: F2TCM, flow-modified 2-tissue compartment model; JWL, Johnson-
Wilson-Lee; S2TCM, standard closed 2-tissue compartment model; CA(t), concentration 
of free tracer in arterial blood; CV(t), concentration of free tracer in venous blood; CE(t) 
are concentration of free tracer in tissue; CM(t), concentration of bound tracer; F, blood 
flow to the tissue voxel; Vb, voxel blood volume; K1, influx rate constant of tracer into 
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the tissue; k2, efflux rate constant from tissue into blood vessels; k3, binding rate constant 
to the target; k4, dissociation rate constant from the target. 
 
Besides dependent on the intrinsic properties of the tissue as shown in figure 1.1, the tissue 
tracer uptake curve is also dependent on the arterial tracer concentration. Provided CT and 
PET image signal is linearly related to tracer concentration and the tissue properties are 
stationary (time-invariant), using the principle of linear supposition, the tissue tracer uptake 
curve is related to the arterial tracer concentration by the following convolution 
relationship:  
𝑄(𝑡) = 𝐶𝑉(𝑡) + 𝐶𝐸(𝑡) + 𝐶𝑀(𝑡) = 𝐹 ∙ 𝐶𝑎(𝑡) ∗ 𝑅(𝑡) (1.1) 
where  is the convolution operator. R(t) is the impulse residue function which is a 
mathematical construct that describes the tissue uptake (wash-out) curve that is measured 
by the CT or PET scanner over time if a unit amount of tracer is instantaneously deposited 
in the tissue (that is, Ca(t) is a delta function, (t)). In this formulation, all the tissue 
properties, except for blood flow, is encapsulated in R(t). For the model presented in figure 
1.1, R(t) can be expressed as a function of the following parameters – To, W, G, α, H and 
β: 
𝑅(𝑡) = {
0.0                                                                 0 < 𝑡 ≤ 𝑇𝑜
1.0                                                      𝑇𝑜 < 𝑡 ≤ 𝑇𝑜 + 𝑊
𝐺𝑒−𝛼(𝑡−𝑇𝑜−𝑊) + 𝐻𝑒−𝛽(𝑡−𝑇𝑜−𝑊)             𝑡 > 𝑇𝑜 + 𝑊
 (1.2) 
In CTP and dynamic PET, the arterial tracer concentration is monitored at a large artery 
upstream (pulmonary artery for NSCLC); therefore, To is incorporated in R(t) to account 
for the potential tracer arrival time difference between the tissue and the monitored artery 
region. W is the (mean) transit time of the tracer through the vasculature in the tissue. The 
rest of the parameters in which R(t) is expressed is related to the model parameters in figure 
1.1 as follows: 
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𝐺 = 𝐾1 (
𝑘3 + 𝑘4 − 𝛼
𝛽 − 𝛼
)     𝐻 = 𝐾1 (
𝑘3 + 𝑘4 − 𝛽
𝛼 − 𝛽
) 
𝛼, 𝛽 =
(𝑘2 + 𝑘3 + 𝑘4) ∓ √(𝑘2 + 𝑘3 + 𝑘4)2 − 4𝑘2𝑘4
2
 
(1.3) 
The tumour time-activity curve is fitted with the model and arterial time-activity curve 
(Equation 1.1) to estimate the model parameters: F, Vb, K1, k2, k3, and k4. In the fitting 
process, the model parameters are iteratively changed until the sum of squared deviations 
between the modelled curve, as calculated from equation 1.1, and the measured tumour 
time-activity curve is minimized. 
1.9 Overall Research Goal and Objectives 
The current paradigm of PET/CT in cancer relies heavily on tumour size and tracer uptake. 
Clinical guidelines, RECIST and PERCIST, use tumour size and tracer uptake to assess 
the treatment response of lung cancer by taking images before and after the treatment. 
Primary prostate tumour nodule is detected and localized by the high tracer uptake for 
diagnosis. As mentioned in the section 1.8, the uptake of a tracer can lead to a misleading 
interpretation of tumour activity because the tracer uptake alone does not explain the 
multitude physiologic/molecular processes involved. 
Therefore, the overall goal/object of this Ph.D. dissertation focused on developing a 
sensitive method to monitor its treatment response and diagnose cancer using quantitative 
dynamic PET and CT techniques for assessing the physiologic/molecular characteristics of 
tumours with dynamic PET and CTP using clinical PET/CT scanners to improve clinical 
decisions made based on such imaging results.  
This thesis was divided into the following goals: 
1. Assessing imaging-based biomarkers from quantitative dynamic [18F]FDG PET 
and CT perfusion imaging to evaluate tumour response to SABR. 
25 
 
2. Evaluating whether imaging biomarkers could predict the true pathologic complete 
response (pCR) of lung cancer to SABR using quantitative dynamic [18F]FDG PET 
and CT perfusion imaging. 
3. Investigating whether the difference between [18F]FCH and [18F]DCFPyL can be 
explained by their kinetic behaviour in prostate cancer and developing a sensitive 
method to detect and localize DIL using quantitative dynamic [18F]FCH or 
[18F]DCFPyL PET, validated using prostate sextant biopsy. 
4. Developing a sensitive method to detect and localize DIL using quantitative 
dynamic [18F]DCFPyL PET and CT perfusion imaging, validated using digital 
histopathology images. 
1.10 Thesis Outline 
 Chapter 2: Assessment of tumour response after stereotactic 
ablative radiation therapy for lung cancer: A prospective 
quantitative hybrid [18F]FDG-PET and CT perfusion study 
The research goal of this work was assessing imaging-based biomarkers from quantitative 
dynamic [18F]FDG PET and CT perfusion imaging to evaluate tumour response to SABR.. 
This study was a part of the A Phase II Trial Measuring the Integration of Stereotactic 
Radiotherapy Plus Surgery in Early Non-Small Cell Lung Cancer (MISSILE-NSCLC) 
study (ClinicalTrials.gov identifier: NCT02136355). Parameters from dynamic [18F]FDG 
PET and CTP imaging from pre-SABR and 8-week post-SABR images were analyzed, and 
pre- vs. post-SABR parameters of tumour lesions were compared. We hypothesized that 
metabolism from [18F]FDG PET and perfusion from CTP of the NSCLC tumour would 
decrease significantly following SABR treatment, and these metabolic and perfusion 
parameters could be used to differentiate between radiation injury from SABR and residual 
tumour. 
 Chapter 3: Predicting pathological complete response (pCR) 
after stereotactic ablative radiation therapy (SABR) of lung 
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cancer using quantitative dynamic [18F]FDG PET and CT 
perfusion: A prospective exploratory clinical study 
The research goal of this work was evaluating whether imaging biomarkers could predict 
the treatment outcome using quantitative dynamic [18F]FDG PET and CT perfusion 
imaging. These parameters were validated using the true pCR of lung cancer to SABR. 
This study was a part of the MISSILE-NSCLC study (ClinicalTrials.gov identifier: 
NCT02136355) as Chapter 2. The parameters from pre-SABR and 8-week post-SABR 
were compared to the true pCR. The NSCLC was explanted for histological correlation, 
and the surgical resection was performed at 10-week post-SABR. We hypothesized that 
quantitative dynamic PET/CT imaging parameters could estimate tumour response to 
SABR better than size measurement and tracer uptake. 
 Chapter 4: Dynamic [18F]DCFPyL-PET of Dominant 
Intraprostatic Lesion: Comparison to [18F]fluorocholine-PET 
using Kinetic Analysis 
The research goal of this work was investigating whether the difference between [18F]FCH 
and [18F]DCFPyL can be explained by their kinetic behaviour in prostate cancer. An 
additional research goal was developing a sensitive method to detect and localize DIL using 
quantitative dynamic [18F]FCH or [18F]DCFPyL PET and validating using prostate sextant 
biopsy. This study was a part of Multi-modality Prostate Cancer Image Guided 
Interventions (IGPC-2) study (ClinicalTrials.gov identifier: NCT04009174). The patients 
underwent dynamic [18F]FCH or [18F]DCFPyL PET for 22 minutes, and the kinetic 
parameters were compared. We hypothesized that the differences between the PET images 
obtained with [18F]FCH and [18F]DCFPyL could be explained by their kinetic behaviour. 
Moreover, dynamic [18F]DCFPyL PET imaging for less than 30 minutes would be able to 
estimate kinetic model parameters that are more sensitive than SUV in differentiating DIL 
from benign tissue. 
 Chapter 5: Validating Dynamic [18F]DCFPyL PET and CT 
Perfusion Imaging Against Digital Histopathology for 
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Detection and Localization of Dominant Intraprostatic 
Lesions in Prostate Cancer 
The research goal of this work was Developing a sensitive method to detect and localize 
DIL using quantitative dynamic [18F]DCFPyL PET and CT perfusion imaging. The 
imaging parameters were validated using digital histopathology images, which is the 
ground truth. This study was a part of the IGPC-2 study (ClinicalTrials.gov identifier: 
NCT04009174) as Chapter 4. In order to validate using digital histopathology images, All 
corresponding PET and CT maps were co-registered to the digital pathology images using 
fiducial markers and anatomical structures/landmarks. We hypothesized that the kinetic 
parameters from dynamic [18F]DCFPyL PET could detect and localize with sensitivity and 
specificity greater than 90%. 
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Chapter 2  
2 Assessment of tumour response after stereotactic 
ablative radiation therapy for lung cancer: A prospective 
quantitative hybrid [18F]FDG-PET and CT perfusion 
study 
The contents of this chapter were previously published in the Journal of Medical Imaging 
and Radiation Oncology by Dae-Myoung Yang, David Palma, Alexander Louie, Richard 
Malthaner, Dalilah Fortin, George Rodrigues, Brian Yaremko, Joanna Laba, Stewart 
Gaede, Andrew Warner, Richard Inculet and Ting-Yim Lee.  
Yang et al. Assessment of tumour response after stereotactic ablative radiation therapy for 
lung cancer: A prospective quantitative hybrid 18F-fluorodeoxyglucose-positron emission 
tomography and CT perfusion study. J Med Imaging Radiat Oncol 2019 Feb; 63(1):94-
101. DOI: 10.1111/1754-9485.12807. Epub 2018 Oct 3. Permission to reproduce this 
article was granted by John Wiley & Sons, Inc. and is provided in Appendix A. 
2.1 Introduction 
Non‐small cell lung cancer (NSCLC) is the leading cause of cancer death worldwide and 
poses a significant public health problem [1]. While many early‐stage NSCLC patients 
with localized disease are treated with lobectomy [2], for those who are medically 
inoperable or refuse surgery, stereotactic ablative radiation therapy (SABR) is now 
considered a standard treatment option. SABR is a radiation treatment that administers a 
high dose of radiation precisely to small tumours in a small number of fractions [3]. Studies 
have shown that SABR has a 3‐year local control rate of approximately 90% [4] and 
improved local control and overall survival compared to conventional, older radiation 
techniques [5]. 
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Despite the promising reported results with SABR, an important obstacle has been the 
difficulty in assessing response after treatment. Radiation‐induced lung injury (RILI), 
which is often asymptomatic, can manifest as radiation pneumonitis and fibrosis, in the 
acute (≤6 months) and late (>6 months) post‐treatment periods [6]. On CT, both of these 
normal tissue manifestations of RILI are difficult to differentiate from recurrence after 
treatment [7], partly because RILI can have similar size and morphology to a recurrent 
tumour [8,9]. 
Hybrid positron emission tomography (PET) and computed tomography (CT) imaging 
with 18F‐labelled fluorodeoxyglucose ([18F]FDG) are a standard clinical imaging modality 
which allows contemporaneous PET metabolic imaging and CT anatomical and perfusion 
imaging of a tumour during a single diagnostic session [10,11]. A low PET/CT‐
measured [18F]FDG standardized uptake value (SUV), which is a surrogate of a tumour 
hypometabolic activity, was found to be predictive of treatment response to both traditional 
fractionated radiotherapy and SABR in NSCLC [12-14]. Conversely, a high SUV, as a 
surrogate of hypermetabolic activity, has been observed in RILI due to inflammatory 
response following SABR, but may also represent recurrence [15]. 
However, because distinguishing RILI from recurrence is difficult [6] with SUV measured 
with standard PET/CT, better imaging modalities are needed. Two candidate modalities 
are CT perfusion (CTP) [16] and dynamic [18F]FDG PET [17]. CTP can monitor the 
destruction of blood vessels (a potential target of SABR) and may also provide a surrogate 
marker of hypoxia [18-20]. CTP also has the practical advantage that it can be conveniently 
combined with dynamic [18F]FDG PET on PET/CT scanners. Dynamic [18F]FDG PET 
tracks tracer uptake at the target lesion over time, allowing for kinetic analyses that may 
better be able to distinguish tumour from RILI. 
The goal of this correlative study was to assess the treatment‐induced changes in CTP and 
dynamic [18F]FDG PET after SABR, to provide possible candidate biomarkers for future 
correlation with response and long‐term survival outcomes. 
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2.2 Methods 
 Patient characteristics 
This analysis represents a correlative study within an ongoing phase II clinical trial 
(NCT02136355; MISSILE‐NSCLC). The phase II study itself evaluates the combination 
of SABR followed by surgery in the treatment of stage T1 or T2a NSCLC (Fig. 2.1). 
Patients aged 18 or older with early‐stage (T1 or T2a) histologically confirmed NSCLC, 
up to 5 cm in diameter and without nodal metastases (N0, M0) were recruited. The study 
was approved by Institutional Research Ethics Board (REB). All participants in this study 
provided written informed consent before the beginning of the study. Patients who had 
severe medical comorbidities or other contraindications to radiotherapy or surgery, prior 
history of lung cancer within 5 years, prior thoracic radiation at any time and allergic 
reactions to the CT contrast were excluded. Pregnant or lactating women were also 
excluded. 
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Figure 2.1: Schema of the study protocol. 
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 Study protocol 
Participants completed a full course of stereotactic ablative radiotherapy, surgery and 
follow‐up visits according to the schedule in Figure 2.1. Imaging included sequential 
dynamic [18F]FDG‐PET and CTP scan in this order with a hybrid PET/CT scanner one 
before and one 8‐week post‐SABR. SABR was delivered using a risk‐adapted method, with 
the dose and the number of fractions dependent on the size and location of the tumour. 
Tumours ≤3 cm surrounded by lung parenchyma received 54 Gy in three fractions; 
tumours abutting the chest wall or >3 cm received 55 Gy in five fractions; and tumours 
within 2 cm of the mediastinum or brachial plexus received 60 Gy in eight fractions. 
Individual fractions were delivered every second day, on weekdays. 
 Dynamic [18F]FDG-PET image acquisition 
Dynamic [18F]FDG‐PET was acquired on a Discovery VCT (GE Healthcare, Waukesha, 
WI, USA) PET/CT scanner. A CT localization scan was first taken with patients lying in a 
supine position on the patient couch. The dynamic [18F]FDG‐PET scan covering the 
primary tumour and pulmonary artery (for the arterial time-activity curve for subsequent 
kinetic analysis) was acquired with the patient in the same position as the CT scan and 
breathing quietly after a bolus injection of [18F]FDG at a dosage of 5 MBq/kg. The 60 min 
dynamic acquisition was divided into frames of variable durations: 6 at 5 s, 6 at 10 s, 3 at 
20 s, 5 at 30 s, 5 at 60 s, 8 at 150 s and 6 at 300 s. [18F]FDG SUV was measured on the 
average of the last six dynamic PET images which was equivalent to 30 minutes of 
acquisition at 30 minutes post‐injection. 
 CT perfusion image acquisition 
CT perfusion scan was performed immediately after the dynamic [18F]FDG‐PET scan 
without moving the patient and also under quiet breathing. The CTP images were acquired 
over 2 min using a shuttle mode where two contiguous 4 cm sections of the thorax covering 
the NSCLC and the pulmonary artery, identified from the CT localization scan, were 
alternately scanned starting 6s before a bolus injection of contrast agent (Isovue 370, 
Bracco Diagnostic Inc., Monroe Township, NJ, USA) at a dosage of 0.7 mL/kg and a rate 
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of 3 mL/s into an antecubital vein. The CTP images were acquired with the following 
protocol: 120 kVp, 50 mAs, 32 × 1.25 mm slices at intervals of 2.8 s for first 1 min then 
15 s for the next 2 min. 
 Dynamic [18F]FDG‐PET and CTP analysis 
For the pre‐SABR study, a region of interest (ROI) was drawn manually around the ‘solid’ 
NSCLC in the [18F]FDG SUV image. For the post‐SABR study, if a tumour had been 
reduced to a viable rim around a ‘necrotic’ core, two ROIs were drawn – one for the outer 
and one for the inner boundary – to isolate the rim from the core. The maximum SUV 
(SUVmax) and mean SUV (SUVmean) from all NSCLC ROIs were determined. For kinetic 
analysis of dynamic [18F]FDG‐PET, the arterial time-activity curve (TAC) was obtained 
from the pulmonary artery, and primary tumour TAC was obtained by finding the area‐
weighted average of NSCLC ROI TACs from all slices. Kinetic parameters – K1 (influx 
rate constant) in mL/min/g, k2 (efflux rate constant) in min
−1, k3 (binding rate constant) in 
min−1, k4 (dissociation rate constant) in min
−1 and Ki = K1k3/(k2 + k3 + k4) (net 
uptake/metabolic rate constant) in mL/min/g were estimated by deconvolving the arterial 
from the primary tumour TAC using the standard two extravascular tissue compartment 
model as modified by the Johnson–Wilson–Lee (JWL) model (see Appendix A) to account 
for blood flow delivery of and permeation of the blood–tumour barrier by [18F]FDG. An 
in‐house MATLAB program iteratively adjusted the model parameters until the sum of 
squared deviations of the fitted TAC, calculated as the convolution of the input TAC and 
the flow scaled impulse residue function of the JWL model, from the primary tumour TAC 
was minimized. Figure 2.2 shows the input and primary tumour average TAC from one 
patient. 
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Figure 2.2: A pulmonary artery time-activity curve (black) and the averaged time-
activity curves from primary tumour (grey, scaled up by 10× to improve visibility) of a 
patient.  
Abbreviations: NSCLC, non‐small cell lung cancer. 
 
For CTP analysis, the acquired free‐breathing images were registered using non‐rigid 
image registration (prototype algorithm from GE healthcare) to minimize breathing motion 
before functional maps, including average, blood flow (BF) in mL/min/100 g, blood 
volume (BV) in mL/100 g, mean transit time (MTT) in second and vessel permeability 
surface product (PS) in mL/min/100 g, were generated with CT perfusion (GE Healthcare). 
The CTP average maps were used to determine the largest lesion diameter (LD) in mm and 
to manually draw the NSCLC ROIs in all slices as in the analysis of [18F]FDG‐PET SUV 
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images. These ROIs were then superimposed on the other functional maps to obtain the 
area‐weighted BF, BV, MTT and PS for the primary tumour. 
 Statistical analysis 
Descriptive statistics were generated for clinical and pathological characteristics of all 
patients and tumours (n = 31). To compare the pre‐ vs. post‐SABR [18F]FDG metabolic 
and CTP parameters of tumours, the Wilcoxon matched‐pair signed‐rank test was used to 
find imaging‐based potential biomarkers of tumour response after SABR. All statistical 
analyses were performed using SPSS (IBM SPSS Statistics 23, IBM Analytics), with two‐
sided statistical testing at the 0.05 significance level. 
2.3 Results 
 Patient cohort and characteristics 
Between September 2014 and September 2017, 40 patients were enrolled in the MISSILE 
study. Among them, 31 patients attended both imaging sessions and were eligible for this 
correlative study; 29 of these patients had both dynamic [18F]FDG‐PET and CTP imaging 
at each session while the remaining two patients did not have CTP imaging due to high 
serum creatinine level. All patients had only one primary tumour. Table 2.1 shows the 
clinical–pathological characteristics of the patients. There were 14 male and 17 female 
patients in this study. All patients had early stage (T1 or T2a) histologically confirmed 
NSCLC without nodal metastases (N0, M0). All patients completed SABR without 
complications or interruptions. 
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Table 2.1: Clinical–pathological characteristics of patients and tumours (n = 31) 
Characteristics Data 
Age (years) – mean ± SD (range) 67.7 ± 8.5 (43.5-82.9) 
Height (cm) – mean ± SD (range) 167.3 ± 9.3 (152-189) 
Weight (kg) – mean ± SD (range) 77.0 ± 17.1 (49-106) 
Sex – n(%)  
Male 14 (45.2) 
Female 17 (54.8) 
Tumour Stage – n(%)  
T1 23 (74.2) 
T2a 8 (25.8) 
Histology – n(%)  
Adenocarcinoma 20 (64.5) 
Squamous 10 (32.3) 
NSCLC NOS 1 (3.2) 
Abbreviations: NSCLC NOS – Non-small cell lung cancer not otherwise specified 
 
 Comparison of [18F]FDG‐PET/CT perfusion imaging 
parameter 
Table 2.2 shows the summary of [18F]FDG‐PET metabolic parameters (N = 31) and CTP 
haemodynamic parameters (N = 29) from the primary tumours and the relative changes of 
post‐SABR [18F]FDG‐PET and CTP imaging parameters from pre‐SABR. For the 
metabolic parameters, there was a significant decrease in SUVmax (P < 0.001), 
SUVmean (P < 0.001), k3 (P = 0.002) and Ki (P = 0.03) and increase in k4 (P < 0.001). For 
the CTP imaging parameters, only LD showed a significant decrease (P = 0.01). 
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Table 2.2: [18F]FDG‐PET/CTP imaging parameters for the primary tumour pre‐ and post‐
SABR 
 Pre-SABR Post-SABR Δrelative P-Value† 
Dynamic [18F]FDG-PET Data 
SUVmax (g/mL) 7.29 ± 4.78 3.12 ± 1.89 -0.572 <0.001* 
SUVmean (g/mL) 2.93 ± 1.66 1.67 ± 0.80 -0.430 <0.001* 
K1 (mL/min/g) 0.144 ± 0.064 0.154 ± 0.050 0.071 0.474 
k2 (min-1) 0.832 ± 0.465 0.770 ± 0.438 -0.075 0.183 
k3 (min-1) 0.256 ± 0.289 0.123 ± 0.101 -0.518 0.002* 
k4 (min-1) 0.012 ± 0.017 0.055 ± 0.064 3.668 <0.001* 
Ki (mL/min/g) 0.026 ± 0.015 0.019 ± 0.008 -0.272 0.027* 
CTP Data 
LD (mm) 29.0 ± 12.31 25.8 ± 14.13 -0.110 0.010* 
BF (mL/min/100g) 112.01 ± 63.16 93.84 ± 50.97 -0.162 0.198 
BV (mL/100g) 7.14 ± 2.97 6.49 ± 3.53 -0.090 0.336 
MTT (s) 8.67 ± 2.60 8.69 ± 3.77 0.003 0.991 
PS (mL/min/100g) 17.65 ± 10.13 18.25 ± 12.76 0.034 0.957 
Abbreviations: [18F]FDG – 18F-labelled fluorodeoxyglucose; PET – positron emission 
tomography; NSCLC – non-small cell lung cancer; SABR – Stereotactic ablative 
radiation therapy; SUV – standardized uptake values; K1 – influx rate constant; k2 – 
efflux rate constant; k3 – binding rate constant; k4 – dissociation rate constant; Ki – net 
uptake/metabolic rate constant; CTP – CT Perfusion; LD – largest lesion diameter; BF – 
blood flow; BV – blood volume; MTT – mean transit time; PS – vessel permeability 
surface product; †P-values reported from Wilcoxon matched-pair signed-rank test of pre- 
vs. post-SABR; *P<0.05 
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Figure 2.3 plots percentage change of post‐SABR from pre‐SABR in BF, BV and k3, while 
Figure 2.4 that of BF, BV and SUVmax. In each case, the patients can be separated into a 
main and an outlier group. In Figure 2.3, the main group had 22 patients and the outlier 
group 7 patients while in Figure 2.4, there were 23 and 6 in the two groups respectively. 
Also, Figures 2.3 and 2.4 show that k3 was able to separate the main and outlier group 
better than SUVmax. 
 
 
Figure 2.3: 3D scatter plot of percentage change of post‐SABR from pre‐SABR in BF, 
BV and k3. The main cluster group (22 patients, white) and the outlier group (7 patients, 
red).  
Abbreviations: BF, blood flow; BV, blood volume; k3, binding rate constant to the target; 
SABR, Stereotactic ablative radiation therapy. 
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Figure 2.4: Percentage change of post‐SABR from pre‐SABR in BF, BV and SUVmax. 
The main cluster group (23 patients, white) and the outlier group (6 patients, red). 
Abbreviations: BF, blood flow; BV, blood volume; SABR, stereotactic ablative radiation 
therapy; SUV, standardized uptake values. 
 
Even though LD showed a significant decrease after SABR, Patients 11 and 15 developed 
ground‐glass opacity (GGO) after SABR, as a result LD increased. Figure 2.5 shows the 
CT image of pre‐ and post‐SABR of Patient 15. According to RECIST (Response 
Evaluation Criteria in Solid Tumours 1.1) guideline, this patient would be evaluated as 
progressive disease [21]; however, RECIST can be inaccurate after SABR due to RILI. 
Table 2.3 shows that [18F]FDG‐PET/CTP imaging parameters and changes in the 
metabolic and perfusion parameters were different between these two cases. 
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Figure 2.5: Pre‐SABR (left) and post‐SABR (right) CT image of patient 15 who 
developed new opacities post‐treatment, suggestive of radiation‐induced lung injury. 
 
Table 2.3: [18F]FDG‐PET/CTP imaging parameters and the changes in the extracted 
parameters of two patients presenting with ground‐glass opacities 
  Patient 11 Patient 15 
 Pre-SABR Post-SABR Δrelative Pre-SABR Post-SABR Δrelative 
LD (mm) 16.3 26.3 0.613 29.0 49.4 0.703 
SUVmax (g/mL) 1.86 2.64 0.419 8.07 4.26 -0.472 
SUVmean (g/mL) 1.05 1.62 0.537 3.59 1.78 -0.504 
BF 
(mL/min/100g) 
247.74 119.99 -0.516 43.25 87.52 1.023 
BV (mL/100g) 10.16 9.01 -0.114 3.24 6.93 1.143 
MTT (s) 3.65 8.74 1.395 10.62 9.34 -0.120 
PS 
(mL/min/100g) 
19.15 68.73 2.589 9.88 22.54 1.280 
K1 (mL/min/g) 0.098 0.084 -0.144 0.110 0.189 0.713 
k2 (min-1) 0.599 0.332 -0.447 0.597 0.704 0.180 
k3 (min-1) 0.051 0.043 -0.157 0.196 0.175 -0.109 
k4 (min-1) 0.028 0.001 -0.966 0.001 0.083 55.319 
Ki (mL/min/g) 0.007 0.010 0.304 0.034 0.007 0.261 
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Abbreviations: [18F]FDG – 18F-labelled fluorodeoxyglucose; PET – positron emission 
tomography; CTP – CT Perfusion; SABR – Stereotactic ablative radiation therapy; SUV 
– standardized uptake values; K1 – influx rate constant; k2 – efflux rate constant; k3 – 
binding rate constant; k4 – dissociation rate constant; ki – net uptake/metabolic rate 
constant; LD – largest lesion diameter; BF – blood flow; BV – blood volume; MTT – 
mean transit time; PS – vessel permeability surface product 
 
Table 2.4 shows the pre‐ and post‐SABR flow‐metabolism ratio (FMR) values and relative 
changes in pre‐ and post‐SABR FMR values. FMR increased significantly post‐SABR. 
 
Table 2.4: Flow‐metabolism ratio values for the primary tumour pre‐ and post‐SABR 
using [18F]FDG‐PET/CTP 
 Pre-SABR Post-SABR Δrelative P-Value† 
BF/SUVmax 22.83 ± 24.89 42.03 ± 39.69 1.911 0.009* 
BF/SUVmean 50.11 ± 46.76 75.81 ± 86.71 1.067 0.064 
Abbreviations: FMR – Flow-metabolism ratio; [18F]FDG – 18F-labelled 
fluorodeoxyglucose; PET – positron emission tomography; CTP – CT Perfusion; SABR 
– Stereotactic ablative radiation therapy; SUV – standardized uptake values; BF – blood 
flow; †P-values reported from Wilcoxon matched pair signed rank test of pre- vs. post-
SABR; *P < 0.05. 
 
2.4 Discussion 
This study investigated the response of primary NSCLC to SABR using hybrid 
dynamic [18F]FDG‐PET and CTP imaging. Kinetic analysis of [18F]FDG uptake and 
contrast agent uptake revealed significant changes in SUVmax, SUVmean, k3, k4, Ki and LD 
from before to after SABR. As such, hybrid [18F]FDG‐PET and CTP imaging have the 
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potential to evaluate NSCLC response to SABR and can be assessed as possible biomarkers 
in future studies. 
The SUV measures the accumulation of [18F]FDG over a time duration, which in this study 
was from 30 to 60 min after injection of the tracer. The SUV results from the net balance 
of several processes: (i) delivery of [18F]FDG to the tumour site by perfusion; (ii) 
bidirectional exchange (influx or leakage and efflux or back flux) of the tracer between 
vessels and the tumour interstitium; and (iii) binding and disassociation of the tracer from 
its target. Therefore, quantitative measurement using kinetic analysis, as we have done is 
herein, may provide a better measure of these dynamic processes. However, due to its 
simplicity, SUV remains in widespread clinical use despite the potential advantages of 
kinetic analyses. 
The metabolic parameters, SUVmax, SUVmean, k3, k4 and Ki, changed significantly 
following SABR in this study. The binding rate constant, k3, describes the enzymatic 
activity of hexokinase in NSCLC, which catalyses the phosphorylation of [18F]FDG 
to [18F]FDG‐6‐P. The dissociation rate constant, k4, may be ascribed to the activity of 
glucose phosphate dehydrogenase (G6PD) which shunts [18F]FDG‐6‐P into the pentose 
phosphate pathway (PPP). The net uptake/metabolic rate constant, Ki = K1k3/(k2 + k3 + k4), 
accounting for the extraction of [18F]FDG from blood and its net retention in tissue 
as [18F]FDG‐6‐P is the metabolic rate of [18F]FDG (or glucose by analogy). Finally, 
SUVmax and SUVmean reflect the net trapping of [
18F]FDG‐6‐P from the balance of 
hexokinase and possibly G6PD activity. These quantitative parameters showed that SABR‐
treated NSCLC had decreased metabolic activity (glucose metabolic rate), decreased 
glucose phosphorylation and possibly increased glucose phosphate dehydrogenase activity 
albeit that hexokinase exceeded G6PD activity pre‐ and post‐SABR. 
Due to the abnormally high metabolic demand from uncontrolled proliferation, a 
characteristic of certain cancer cells is hyperactive PPP [22], initiated by the upregulation 
of G6PD [23,24]. In fact, NSCLC has been found to have elevated levels of expression and 
activity of G6PD [25]. PPP generates ribonucleotides and NADPH, required for fatty acid 
synthesis and reactive oxygen species deactivation [26,27]. An elevated level of reactive 
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oxygen species provokes the PPP activity as a protective response mechanism [28]. Further 
research is required to correlate quantitative k4 values with immunohistochemical markers 
associated with PPP. 
The development of post‐treatment consolidation and GGO present a challenge in 
assessing tumour response using RECIST guidelines alone. These changes seen in CT may 
represent tumour recurrence, RILI or a combination of both. The results from Patients 11 
and 15, highlighted in Table 2.3, demonstrate that size measurements may not reflect 
underlying biological processes as assessed by these other, more novel, imaging 
modalities. Future studies correlating histopathology of explanted tumour with perfusion 
and metabolic parameters could identify methods to reliably characterize SABR outcomes. 
Hybrid PET/CT imaging enabled the ability to measure tumour [18F]FDG uptake, tumour 
perfusion by CTP and FMR in the same imaging session. The observed mismatch between 
tumour blood flow and glucose metabolism was hypothesized to be associated with tumour 
hypoxia. Table 2.4 showed that FMR increased suggesting that hypoxia if present pre‐
SABR decreased after SABR. This observation suggests that further studies to correlate 
patient outcome with FMR are warranted. FMR can potentially be used as an imaging 
biomarker to predict the outcome of SABR. Tumour hypoxia is resistance to radiation 
therapy. When a tumour has low FMR, it can be hypoxic due to flow‐metabolism 
mismatch, as a result resistant to SABR. If the same tumour persists in having a low FMR 
value post‐SABR, it could mean the tumour is still hypoxic which possibly predicts that 
SABR may not be effective in tumour control. Further investigation should be performed 
using FMR pre‐ and post‐SABR and histopathology of an explanted tumour to identify a 
correlation between FMR and hypoxia of NSCLC. 
In a previous study with NSCLC patients, [18F]FDG SUVmax and SUVmean correlated with 
the immunohistochemical marker Ki67 (a proliferation marker), whereas BF and 
BV correlate with microvessel density [29]. Therefore, results from our study suggest that 
SABR was efficient in suppressing the proliferation of tumour cells. In our study, post‐
SABR BF and BV were assessed in a viable tumour surrounding the necrotic core created 
by the treatment. There were no significant decreases in BF nor BV after SABR. 
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In summary, kinetic analysis using JWL model of [18F]FDG uptake and contrast agent 
uptake reveals significant changes in SUVmax, SUVmean, k3, k4, Ki, LD and FMR with 
SUVmax before and after SABR. Hybrid [
18F]FDG‐PET/CTP showed [18F]FDG uptake and 
perfusion parameters provide complementary functional information. Ultimately, these 
potential biomarkers will need to be correlated with long‐term outcomes in validated 
studies to determine their clinical utility. 
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Chapter 3  
3 Predicting pathological complete response (pCR) after 
stereotactic ablative radiation therapy (SABR) of lung 
cancer using quantitative dynamic [18F]FDG PET and 
CT perfusion: A prospective exploratory clinical study 
The contents of this chapter were previously submitted in Radiation Oncology by Dae-
Myoung Yang, David A. Palma, Keith Kwan, Alexander V. Louie, Richard Malthaner, 
Dalilah Fortin, George B. Rodrigues, Brian P. Yaremko, Joanna Laba, Stewart Gaede, 
Andrew Warner, Richard Inculet and Ting-Yim Lee.  
3.1 Introduction 
Stereotactic ablative radiation therapy (SABR) is effective in treating inoperable stage I 
non-small cell lung cancer (NSCLC) [1]. The majority of studies of using SABR for this 
indication report a 3-year local control rate of approximately 90%, based on imaging [2]. 
However, tumour response after SABR is difficult to evaluate using current clinical 
evaluation guidelines, such as RECIST (Response Evaluation Criteria in Solid Tumours 
version 1.1) and PERCIST (PET Response Criteria in Solid Tumours version 1.0) 
guidelines.  
After SABR, more than 50% of patients can have lung density changes on computed 
tomography (CT) imaging which could be due to radiation-induced lung injury (RILI) or 
tumour recurrence [3]. However, these changes do not have distinctive patterns that easily 
differentiate between RILI and recurrence. Moreover, the inflammatory RILI response 
shows a high fluorine-18 fluorodeoxyglucose ([18F]FDG) standardized uptake value (SUV) 
on positron emission tomography (PET) imaging, implying a hypermetabolic state as in 
tumour recurrence [4]. Because RILI and recurrence can have similar size, morphology 
and [18F]FDG uptake [5,6], differentiating these entities based on post-SABR CT and PET 
according to RECIST and PERCIST criteria can be difficult. 
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CT Perfusion (CTP) and dynamic [18F]FDG-PET (as opposed to static SUV measurement 
taken at one time point) can be used to understand tissue hemodynamics (delivery and 
permeation of the endothelial barrier) and glucose metabolism, respectively. The two 
modalities have a practical advantage that they can be conveniently combined together in 
a single study session on a PET/CT scanner. Evaluation of perfusion, blood volume, and 
glucose uptake rate could be more sensitive than either RECIST or PERSIST at monitoring 
the response to SABR. The purpose of the present study was to evaluate whether the 
imaging biomarkers from CTP and dynamic [18F]FDG-PET could predict the true 
pathologic complete response (pCR) of NSCLC to SABR. To our knowledge, this is the 
first prospective study evaluating imaging-based biomarkers to predict pCR after SABR 
treatment. 
3.2 Methods 
 Patients Characteristics 
This analysis was a correlative study within a phase II clinical trial (NCT02136355; 
MISSILE-NSCLC), and the primary analysis and full protocol have been published 
previously [7]. The phase II study evaluated the combination of SABR followed by surgery 
in the treatment of early-stage (T1 or T2a) NSCLC. The study was approved by the 
Institutional Research Ethics Board. All participants in this study provided written 
informed consent. Eligible patients aged 18 or older had histologically confirmed early-
stage NSCLC (≤5 cm), no evidence of nodal or distant metastases (N0, M0), Eastern 
Cooperative Oncology Group (ECOG) status 0-2, life expectancy greater than 6 months 
and predicted post-operative forced expiratory volume in 1 second (FEV1) of 30% or 
greater. Exclusion criteria included severe medical comorbidities or other contraindications 
to radiation therapy or surgery, prior history of lung cancer within 5 years, prior thoracic 
radiation at any time, and allergy to CT contrast. Pregnant or lactating women were also 
excluded. 
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 Study Protocol 
After enrollment in this study, participants underwent the pre-SABR imaging session 
consisting of dynamic [18F]FDG-PET and CTP imaging in this order with a hybrid PET/CT 
scanner. At 8-weeks post-SABR, participants were again imaged as in the pre-treatment 
session. Finally, at 10-weeks post-SABR, the tumour was resected. 
 Dynamic [18F]FDG-PET and CT Perfusion (CTP) Imaging 
Acquisition and Analysis 
Dynamic [18F]FDG-PET was acquired on a Discovery VCT (GE Healthcare, Waukesha, 
WI, USA) PET/CT scanner. Prior to the dynamic PET scan, a CT localization scan for 
attenuation correction was obtained with patients lying supine on the patient couch. For 
the dynamic PET scan a bolus injection of [18F]FDG at a dosage of 5 MBq/kg was given, 
with the patient in the same position as the CT scan. Simultaneous with the injection, 
while the patient was breathing quietly, images covering the primary tumour and 
pulmonary artery were acquired for 60 minutes (min) with a variable frame length of 5 
seconds (s) (6 frames), 10 s (6 frames), 20 s (3 frames), 30 s (5 frames), 60 s (5 frames), 
150 s (8 frames), and 300 s (6 frames).  
The CTP scan was performed immediately after the dynamic [18F]FDG-PET PET scan 
without moving the patients and also under quiet breathing. The scan was acquired over 3 
min using a shuttle mode where two contiguous 4 cm sections of the thorax covering the 
primary tumour and the pulmonary artery, identified from the CT localization scan, were 
alternately scanned starting 6 seconds before a bolus injection of contrast agent (Isovue 
370, Bracco Diagnostic Inc., NJ, USA) at a rate of 3 mL/s and a dosage of 0.7 mL/kg into 
an antecubital vein. The CTP images were acquired using 32 x 1.25 mm slices, 120 kVp 
and 50 mAs at intervals of 2.8 s for first 1 min and then every 15 s for the next 2 min.  
From the dynamic [18F]FDG-PET data, kinetic parameters – K1 (influx rate constant) in 
mL/min/g, k2 (efflux rate constant) in min
-1, k3 (binding rate constant) in min
-1, k4 
(dissociation rate constant) in min-1, Ki = K1k3/(k2+k3+k4) (net uptake/metabolic rate 
constant) in mL/min/g and DV = (K1/k2)(1+k3/k4) (distribution volume) in mL/g were 
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estimated using a previously developed flow-modified two-tissue compartment model [8] 
to account for blood flow delivery and birdirectional permeation of the blood-tumour 
barrier by [18F]FDG. In addition to the kinetic analysis, the last six dynamic PET images 
equivalent to 30 min of acquisition starting at 30 min post-injection were averaged together 
for SUVmax and SUVmean measurements. Commercial software (CT Perfusion, GE 
Healthcare) was used to generate functional maps, including average, blood flow (BF) in 
mL/min/100g, blood volume (BV) in mL/100g, mean transit time (MTT) in seconds and 
vessel permeability surface product (PS) in mL/min/100g, from the CTP imaging. 
 Stereotactic Ablative Radiation therapy, Surgery and 
Determination of pCR Status 
SABR was delivered using a risk-adapted method, with the dose and the number of 
fractions dependent on the size and location of the tumour. 54 Gy in 3 fractions were 
delivered to tumours ≤ 3 cm and surrounded by lung parenchyma; 55 Gy in 5 fractions to 
tumours abutting the chest wall or > 3 cm; and 60 Gy in 8 fractions to tumours within 2 
cm of the mediastinum or brachial plexus [9,10]. Individual fractions were delivered 
every second day, on weekdays. All patients underwent 4D planning CT simulation. 
Respiratory gating was considered in cases where motion was > 7 mm in any direction. 
The detail protocol of SABR and surgery have been described in the original publication 
[7]. 
Surgery, either lobectomy or sublobar resection, was performed at our high-volume tertiary 
center after the 2nd set of imaging, at 10 ± 2 weeks following SABR, to allow sufficient 
time for a pathological response. The at-risk hilar and mediastinal nodes were also sampled 
at the time of resection. The resected tumour was oriented by the surgeon to its in-vivo 
position and submitted for histopathology. The pCR status of the primary tumour was 
determined by the pathologist based on standard hematoxylin and eosin staining criteria, 
as described in the original publication [7]. 
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 Statistical Analysis 
Recursive partitioning analysis (RPA) using decision trees was performed to create a 
predictive model of pCR status of patients. A minimum number of 5 observations in a node 
were required to enable further splitting, followed by trimming of less important 
downstream branches as needed. The performance of the RPA model and RECIST 
complete response (CR)-partial response (PR) and PERCIST complete metabolic response 
(CMR)-partial metabolic response (PMR) criteria in predicting pCR was compared using 
receiver operating characteristic curves (ROC). Statistical analyses were performed using 
SAS version 9.4 software (SAS Institute, Cary, NC, USA) and the R language for statistical 
computing version 3.5.0 (open source, www.r-project.org), using two-sided statistical 
testing at the 0.05 significance level. 
3.3 Results 
Between September 2014 and September 2017, 40 patients were enrolled in this study, of 
which 35 were evaluable for the primary endpoint, as described in the original paper [7]. 
Of those 35, 26 patients completed both imaging sessions and were available to be 
analyzed. The other 9 declined or was unavailable for one or both of the imaging sessions. 
Patient enrollment is summarized in Fig. 3.1. Table 3.1 shows the clinical-pathologic 
characteristics of the patients. There were 13 male and 13 female patients in this sub-study. 
Of the 26 patients included herein, 13 patients had a pCR, and 13 patients had residual 
disease. 
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Figure 3.1: Summary of patient enrollment. 
Abbreviations: SABR = Stereotactic ablative radiation therapy; FDG = 
Fluorodeoxyglucose; PET = Positron emission tomography; CTP: Computed tomography 
perfusion 
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Table 3.1: Baseline tumour, patient and treatment characteristics for all patients (n=26) 
Characteristic All Patients (n=26) 
Age at Registration – median, (min, max) 68.7 (43.5, 82.9) 
Gender – n(%) 
Male 
Female 
 
13 (50.0) 
13 (50.0) 
Primary Lung Location – n(%) 
Left Upper Lobe 
Left Lower Lobe 
Right Upper Lobe 
Right Middle Lobe 
Right Lower Lobe 
 
2 (7.7) 
3 (11.5) 
13 (50.0) 
4 (15.4) 
4 (15.4) 
T Stage – n(%) 
T1 
T2 
 
20 (76.9) 
6 (23.1) 
Histology – n(%) 
Adenocarcinoma 
Squamous 
NSCLC NOS 
 
16 (61.5) 
9 (34.6) 
1 (3.9) 
Pre-treatment FEV1 – mean ± SD 73.7 ± 16.4 
Post-treatment FEV1 – mean ± SD 75.1 ± 20.2 
Change FEV1 – mean ± SD 0.1 ± 13.5 
Dose Fractionation – n(%) 
54 Gy in 3 Fractions 
55 Gy in 5 Fractions 
60 Gy in 8 Fractions 
 
5 (19.2) 
15 (57.7) 
6 (23.1) 
Surgery – n(%) 26 (100) 
Surgery Type – n(%) 
Lobectomy 
Wedge Resection 
 
18 (69.2) 
8 (30.8) 
Surgical Approach – n(%) 
VATS 
VATS converted to open 
Open 
 
21 (80.8) 
3 (11.5) 
2 (7.7) 
Abbreviations: NSCLC NOS = Non-small cell lung cancer not otherwise specified; FEV1 
= Forced expiratory volume in 1 second; VATS = Video-Assisted Thoracoscopic Surgery  
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The RPA identified three patient groups based on tumour blood volume before SABR 
(BVpre-SABR) and change in SUVmax (ΔSUVmax) as shown in Fig.3. 2. According to the RPA, 
group 1 was defined as baseline tumour blood volume (BVpre-SABR) ≥ 9.3 mL/100g (n=6, 
0% pCR rate). No Group 1 patient showed pCR from the pathological analysis. All 6 
patients had tumour residual disease after SABR treatment. Group 2 was defined by BVpre-
SABR < 9.3 mL/100g and the percent change in SUVmax (ΔSUVmax) ≥ -48.9 % after SABR 
(n=8, 25% pCR rate). Group 3 was defined by BVpre-SABR < 9.3 mL/100g and ΔSUVmax < 
-48.9% after SABR (n=12, 92% pCR rate). 
 
 
Figure 3.2: Recursive Partitioning Tree. 
Abbreviations: BV = Blood volume; SABR = Stereotactic ablative radiation therapy; 
pCR = pathologic complete response; SUV = Standardized uptake value 
 
The RPA model was able to predict pCR with 85% sensitivity, 92% specificity, 92% 
positive predictive value (PPV), 86% negative predictive value (NPV), and concordance 
(area under the ROC curve) of 0.92 (95% confidence interval (CI): 0.82-1.00). In contrast, 
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current clinical RECIST criteria of CR/PR applied to pre- and post-SABR standard-of-care 
CT showed 46% sensitivity, 47% specificity, 38% PPV, 54% NPV, and concordance of 
0.54 (95% CI: 0.34-0.74) in predicting pCR. Furthermore, PERCIST criteria of CMR/PMR 
applied to pre- and post-SABR [18F]FDG scan showed 85% sensitivity, 31% specificity, 
55% PPV, 67% NPV, and concordance of 0.58 (95% CI: 0.35-0.80) in predicting pCR. 
ROC curves are shown in Fig. 3.3. Fig. 3.4 shows increase in lesion diameter on CT and 
decrease in uptake of [18F]FDG in a patient with pCR while Fig. 3.5 shows the opposite in 
another patient with pCR − decreased diameter on CT and increased [18F]FDG uptake.  
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Figure 3.3: ROC Curves. 
Abbreviations: RPA = Recursive partitioning analysis; RECIST = Response Evaluation 
Criteria in Solid Tumours 1.1; PERCIST = Positron Emission Tomography Response 
Criteria in Solid Tumours 1.0 
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Figure 3.4: Example of RECIST Failure. Pre-SABR images of pCR patients on CT, PET 
SUV (range: 0 – 5.0 g/mL), and PET/CT fused are shown in (a), (b) and (c), respectively. 
Post-SABR CT, PET and PET/CT fused images are shown in (d), (e) and (f), 
respectively. 
Abbreviations: RECIST = Response Evaluation Criteria in Solid Tumours 1.1; SABR = 
Stereotactic ablative radiation therapy; pCR = Pathologic complete response; CT = 
Computed tomography; PET = Positron emission tomography; SUV = Standardized 
uptake value 
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Figure 3.5: Example of PERCIST Failure. Pre-SABR images of pCR patients on CT, 
PET SUV (range: 0 – 6.5 g/mL), and PET/CT fused are shown in (a), (b) and (c), 
respectively. Post-SABR CT, PET and PET/CT fused images are shown in (d), (e) and 
(f), respectively. 
Abbreviations: PERCIST = PET Response Criteria in Solid Tumours; SABR = 
Stereotactic ablative radiation therapy; pCR = Pathologic complete response; CT = 
Computed tomography; PET = Positron emission tomography; SUV = Standardized 
uptake value 
 
3.4 Discussion 
This study employed RPA decision trees to predict pCR after SABR in patients with early-
stage NSCLC using biomarkers from [18F]FDG-PET and CTP. Our results suggest that 
pCR of early-stage NSCLC to SABR can be predicted with 85% sensitivity, 92% 
specificity, 92% PPV, and 86% NPV using biomarkers from [18F]FDG-PET and CTP study 
before and 8-10 weeks after treatment.  
In comparison, RECIST and PERCIST criteria showed worse pCR prediction due to 
radiation induced lung injury (RILI) because recurrent tumour can show similar size and 
76 
 
morphology change and [18F]FDG uptake as RILI. Examples from fig. 3.4 and fig. 3.5 may 
indicate why the RECIST and PERCIST criteria lack sensitivity, specificity, PPV and NPV 
in predicting pCR to SABR. To be effective in treating early-stage NSCLC, SABR requires 
better evaluation criteria for response than the current RECIST and/or PERCIST; our study 
suggests that combined [18F]FDG and CTP could be a viable alternative. 
This study suggests that pCR to SABR could be predicted with the BV of NSCLC before 
and change in maximum uptake of [18F]FDG post-treatment. The predictive model using 
RPA decision trees separated SABR patients into three groups: Group 1: patients with 
BVpre-SABR ≥ 9.3 mL/100g; Group 2: patients with BVpre-SABR < 9.3 mL/100g and ΔSUVmax 
≥ -48.9 %; and Group 3: BVpre-SABR < 9.3 mL/100g and ΔSUVmax < -48.9%. 
The limitation of this study is the small sample size. To address this limitation, we used 
RPA to identify imaging-based biomarkers that have potential for predicting pCR rather 
than the conventional logistic regression technique which requires larger sample sizes to 
improve model stability. [11,12] Nevertheless we were able to create a predictive model 
that was significantly better than RECIST and PERCIST criteria; therefore, this RPA 
model warrants future external validation with larger sample size studies. 
3.5 Conclusions 
In conclusion, this study shows that tumour BV before treatment (BVpre-SABR) and change 
in [18F]FDG SUVmax (ΔSUVmax) at 8-10 weeks post-treatment can predict pCR of early-
stage NSCLC to SABR with good sensitivity and high specificity. In comparison, RECIST 
and PERCIST criteria had poorer sensitivity and specificity in pCR prediction. While these 
findings were limited by the reduced sample size, the developed prediction model warrants 
further investigation. 
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Chapter 4  
4 Dynamic [18F]DCFPyL-PET of Dominant Intraprostatic 
Lesion: Comparison to [18F]fluorocholine-PET using 
Kinetic Analysis 
The contents of this chapter were previously submitted in European Journal of Nuclear 
Medicine and Molecular Imaging Research by Dae-Myoung Yang, Fiona Li, Glenn 
Bauman, Joseph Chin, Stephen Pautler, Madeleine Moussa, Irina Rachinsky, John Valliant 
and Ting-Yim Lee. 
4.1 Introduction 
Prostate cancer (PCa) is the most frequent cancer and one of the most common causes of 
cancer death in men in the United States and Canada [1,2]. Positron emission tomography 
(PET) targeting prostate-specific membrane antigen (PSMA), a type II integral membrane 
protein, is generating significant interest recently. PSMA is a highly promising target for 
localizing and detecting PCa because it is overexpressed 100- to 1000-fold in malignant 
compared to benign prostate tissue [3]. Prior to PSMA, choline-based tracers that depend 
on increased phosphorylation of choline in lipid metabolism were widely used [4-6]. In 
comparison, radiotracers targeting PSMA, such as 68Ga-PSMA-11 and [18F]DCFPyL, 
afford better image quality and PCa detection rate than choline-based radiotracers [7-9]. 
Since previous clinical studies had shown that [18F]fluorocholine ([18F]FCH) PET cannot 
differentiate benign hyperplasia from PCa, it is not recommended for localizing PCa [10-
11]. However, PSMA PET requires a longer delayed imaging time than [18F]FCH PET to 
achieve optimal standardized uptake value (SUV) contrast between PCa and background 
[12-17]. For example, it has been advocated that [18F]DCFPyL PET imaging requires 1-2 
h delayed imaging time compared with 7-30 min for [18F]FCH PET [8-11].  
Even though PET SUV with a PSMA ligand, such as [18F]DCFPyL, showed high image 
quality and can visualize small prostate lesions with excellent sensitivity [18], it is a single 
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time point measurement and is unable to completely describe the uptake of the tracer. The 
uptake of PET tracer in tissue, as measured by the SUV, is determined by the combined 
effects of three processes: tracer delivery via blood flow, exchange between vessels and 
tissue, and binding to and dissociation from the target. A single uptake measurement cannot 
differentiate among the 3 different processes [19]. Therefore, SUV is dependent on the 
time after injection when the measurement is made [20]. Moreover, these processes may 
vary among radiotracers, and they can be different among tumours of the same tumour type 
because of tumour heterogeneity. Instead, dynamic PET with its multiple time point 
measurements following injection is suited to dissect the processes involved in the 
distribution and uptake of radiotracers and it can provide additional metrics related to the 
target specific molecular/metabolic processes for potential better differentiation of tumour 
from benign tissue.  
The goal of this study was to investigate whether the different behaviour of [18F]DCFPyL 
and [18F]FCH in PCa can be explained by kinetic analysis and to evaluate which kinetic 
parameters derived from dynamic [18F]FCH and [18F]DCFPyL PET are more sensitive than 
SUV to localize and detect dominant intraprostatic lesion (DIL) identified by prostate 
sextant biopsy report. 
4.2 Methods 
 Patients 
This prospective clinical study was approved by Institutional Research Ethics Board. All 
participants in this study provided written informed consent before the study. Enrolled 
subjects were men with untreated biopsy-proven localized PCa. The inclusion criteria were 
as follows: aged 18 years or older; biopsy confirmed PCa; and suitable for and consenting 
to radical prostatectomy for treatment, or repeat biopsy as the standard of care. 52 PCa 
patients were recruited into the study. The first 25 enrolled patients had dynamic [18F]FCH 
PET, while the last 27 patients had dynamic [18F]DCFPyL PET. However, 23 and 19 
patients received [18F]FCH and [18F]DCFPyL PET, respectively, because of patients 
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withdrawing from the study or failure of tracer production. Fig. 4.1 shows the flow chart 
of the study. 
 
 
Figure 4.1: Study flowchart showing patient enrollment.  
Abbreviations: FCH = Flourocholine; DCFPyL = 2-(3-{1-carboxy-5-[(6-[18F]fluoro-
pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid. 
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 3D-Transrectal Ultrasound (TRUS) Guided Prostate Sextant 
Biopsy 
All patients had undergone systematic TRUS-guided biopsy (6- or 12- core) before the 
dynamic PET scan. The prostate sextants with the highest volume and/or highest grade 
cancer on biopsy were designated as harboring a DIL and this information was extracted 
from the clinical biopsy report by one of the investigators (GB) and the involved sextants 
correlated to the SUV image from the dynamic PET scan (see next section).  
 Dynamic PET Imaging Acquisition 
Dynamic [18F]FCH and [18F]DCFPyL PET imaging were performed on a Discovery VCT 
(GE Healthcare, Waukesha, WI, USA) PET/CT scanner. A CT scan for attenuation 
correction was taken first with patients lying supine on the patient couch. The dynamic 
PET scan set to cover the whole prostate and common iliac arteries was started 
simultaneously as the intravenous injection of 4 MBq/kg (median 381 MBq; range 280-
538 MBq) [18F]FCH or 325 MBq (median 335 MBq; 280-348 MBq) [18F]DCFPyL without 
the patient moving from the CT scan position. The dynamic PET scan was acquired for 22-
min under quiet breathing with variable frame lengths of 10 s (10 frames), 20 s (5), 40 s 
(4), 60 s (4) and 180 s (4). SUV of [18F]FCH or [18F]DCFPyL was measured by averaging 
the last four dynamic PET images which was equivalent to 12 minutes of acquisition 
starting at 10 minutes post-injection. 
 Dynamic PET Imaging Analysis 
The dynamic PET images and SUV images were analyzed on an AW Workstation (AW4.7, 
GE Healthcare). In the DIL region indicated by pre-operative prostate sextant biopsy, 
regions of interest (ROIs) were drawn in all slices showing the largest lesion by 
thresholding SUV  50% of maximum SUV (SUVmax). The same number of benign tissue 
ROIs as DIL ROIs were outlined in benisextant locales not involved according to prostate 
sextant biopsy. For kinetic analysis, the arterial time-activity curve (TAC) was obtained 
from a region inside a common iliac artery. TACs for DIL and benign tissue were obtained 
by finding the area-weighted average of the mean activity in each DIL and benign ROI for 
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all slices. The dynamic TACs of both tracers were analyzed using the flow modified 
standard two extravascular tissue compartment model (F2TCM), as described in a previous 
publication [18]. This model accounts for the combined effects of the three tracer uptake 
processes: tracer delivery via blood flow; bidirectional permeation of the blood-tissue 
barrier during tracer transit through vessels; and binding to and dissociation from the target. 
Kinetic parameters – K1 (influx rate constant) in mL/min/g, k2 (efflux rate constant) in min
-
1, k3 (binding rate constant) in min
-1, k4 (dissociation rate constant) in min
-1, Ki = 
K1k3/(k2+k3+k4) (net uptake rate constant from plasma) in mL/min/g, DV = 
(K1/k2)(1+k3/k4) (distribution volume) in mL/g and k4/k3 (normalized washout rate constant 
(inverse of binding potential)) were estimated by deconvolving the arterial TAC from the 
tissue TAC. A custom developed MATLAB program iteratively adjusted the model 
parameters until the sum of squared deviations of the fitted TAC, calculated as the 
convolution of the arterial TAC and the flow scaled impulse residue function of the 
F2TCM, from the tissue TAC was minimized. 
 Statistical Analysis 
All statistical analyses were performed using SPSS (IBM SPSS Statistics 23, IBM 
Analytics) for 2-sided testing with significance set at P<0.05. For each PET tracer, the 
F2TCM parameters of DIL and benign prostatic tissue were compared using nonparametric 
Wilcoxon matched-pair signed-rank test. The kinetic parameters of [18F]FCH and 
[18F]DCFPyL were compared using the nonparametric Mann-Whitney U test. Logistic 
regression with backward selection was used to determine the most sensitive set of kinetic 
parameters to distinguish DIL from benign tissue for each tracer. From that analysis, 
sensitivity, specificity, positive predictive value (PPV) and negative predictive value 
(NPV) and receiver operating characteristic (ROC) curve of the dynamic [18F]FCH and 
[18F]DCFPyL PET imaging were assessed. 
4.3 Results 
23 patients (median age 62 years, range 49-76 years) and 19 patients (median age 63 years, 
range 53-69 years) received dynamic PET with [18F]FCH and [18F]DCFPyL, respectively 
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(Fig. 4.1). The median pre-operative PSA level within 2 week before the day of the imaging 
session of [18F]FCH PET or [18F]DCFPyL PET was 4.8 ng/mL (range 0.9-15.0 ng/mL) and 
5.4 ng/mL (range 3.5-25.5 ng/mL), respectively. The characteristics of the two patient 
cohorts are listed in Table 4.1. Fig. 4.2 shows the measured arterial and tissue TAC from a 
patient from each cohort, and the fit using the F2TCM. Fig. 4.3 shows maximum intensity 
projections of SUV maps of the same patients, as in Fig. 4.2. 
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Table 4.1: Patient Characteristics 
 [18F]FCH (n=23) [18F]DCFPyL (n=19) P-value 
Age [y] 61.1 ± 6.9 (49-76)* 62.4 ± 4.7 (50-67)* 0.58 
Weight [kg] 93.3 ± 14.3 (67-122)* 86.4 ± 17.1 (30-109)* 0.46 
Height [cm] 175.7 ± 5.0 (168-185)* 177.1 ± 6.3 (165-191)* 0.37 
PSA [ng/mL] 5.9 ± 3.4 (0.9-15.0)* 8.4 ± 5.8 (3.5-25.5)* 0.42 
Histology – n(%) 1.00 
Adenocarcinoma 23 (100) 19 (100)  
pT Stage – n(%) 0.93 
T2a 1 (4.3) 0 (0)  
T2c 12 (52.2) 11 (57.9)  
T3a 5 (21.7) 7 (36.8)  
T3b 5 (21.7) 1 (5.3)  
pN Stage – n(%) 0.79 
N0 19 (82.6) 19 (100)  
N1 1 (4.3) 0 (0)  
NX 3 (13.0) 0 (0)  
Gleason score – n(%) 0.94 
6 (3+3) 2 (8.7) 1 (5.3)  
7 (3+4) 17 (69.6) 16 (84.2)  
7 (4+3) 4 (17.4) 2 (10.5)  
9 (5+4) 1 (4.3) 0 (0)  
Proportion of Prostate 
Involved by Tumour (%) 
14.3 ± 15.5 (1-80)* 13.7 ± 7.7 (5-30)* 0.49 
Note. Data are number of patients, with the percentage in parentheses unless otherwise 
indicated. 
* Data are means ± standard deviation, with the range in parentheses. 
Abbreviations: FCH = Flourocholine; DCFPyL = 2-(3-{1-carboxy-5-[(6-[18F]fluoro-
pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid; PSA = Prostate specific 
antigen 
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Figure 4.2: An iliac artery TAC (gray), the tumour TAC (light gray line with open circle 
marker, scaled up 4x to improve visibility) and the benign tissue TAC (light gray line 
with x marker, scaled up 4x) of a [18F]FCH patient (a) and a [18F]DCFPyL patient (b). 
Both patients had similar prostate cancer characteristics (PSA level 10.3 vs. 12.94 ng/mL; 
Gleason score 7 (3+4), the proportion of prostate involved with tumour 10%). The fitted 
curves (black) for both tracers using the F2TCM showed a strong correlation with 
measured TACs (R2 > 0.93).  
Abbreviations: TAC: Time-activity curve; FCH = Flourocholine; DCFPyL = 2-(3-{1-
carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic 
acid; PSA = Prostate specific antigen; F2TCM = Flow modified standard two 
extravascular tissue compartment model. 
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Figure 4.3: PET/CT Images of the same patients as Figure 4.2 showing maximum 
intensity projection of [18F]FCH PET SUV map in an axial view superimposed on CT (a) 
and in a coronal view by itself (b); the same two views for a [18F]DCFPyL study on 
another patient are shown in (c) and (d). The colour bar shows the scale of SUV. 
Localization of DIL (yellow arrow) with PET in both patients agreed with pre-operative 
prostate sextant biopsy. [18F]DCFPyL SUV map shows superior tumour contrast relative 
to benign prostatic tissue and better localization of DIL than [18F]FCH. 
Abbreviations: PET = Positron emission tomography; CT = Computed tomography; FCH 
= Flourocholine; SUV = Standardized uptake value; DCFPyL = 2-(3-{1-carboxy-5-[(6-
[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid; DIL = 
Dominant intraprostatic lesion. 
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 Comparison of Kinetic Parameters between DIL and Benign 
Tissue Parameters 
Kinetic parameters of DIL were compared with those of benign tissue in Fig. 4.4. For 
[18F]FCH cohort, significant differences in median value of K1 (0.27 vs. 0.23 mL/min/g; 
P<0.001), SUV (3.88 vs. 2.75 g/mL; P<0.001) and DV (6.07 vs. 4.31 mL/g; P=0.04) were 
found. The median values of the same three parameters and also k4/k3 were different 
between DIL and benign tissue for [18F]DCFPyL cohort - K1 (0.30 vs. 0.24 mL/min/g; 
P=0.02), SUV (2.76 vs. 1.96 g/mL; P<0.001), DV (3.89 vs. 1.42 mL/g; P=0.01) and k4/k3 
(0.41 vs. 0.69 unitless; P=0.03). 
 
 
Figure 4.4: Comparison of [18F]FCH and [18F]DCFPyL F2TCM model parameters in 
DIL and benign tissue. Significant difference (P<0.05) is marked with *. 
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Abbreviations: FCH = Flourocholine; DCFPyL = 2-(3-{1-carboxy-5-[(6-[18F]fluoro-
pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid; F2TCM = Flow 
modified standard two extravascular tissue compartment model; DIL = Dominant 
intraprostatic lesion; K1 = Influx rate; k2 = Efflux rate constant; k3 = Binding rate 
constant; k4 = Dissociation rate constant; Ki = Net uptake rate constant from plasma; DV 
= Distribution volume; SUV = standardized uptake value. 
 
 Diagnostic Performance for Detecting and Localizing DIL 
using PET Kinetic Parameters 
For the [18F]FCH group (n=23), using logistic regression with backward elimination of all 
parameters having a univariable logical regression P<0.2, the most sensitive model of PET 
parameters for identifying DIL from benign tissue consisted of SUV alone (P<0.001) - 
sensitivity 82.6%, specificity 87.0%, PPV 86.4%, NPV 83.3%, and area under the ROC 
curve (AUC) 0.88. For [18F]DCFPyL, logistic regression with backward elimination of all 
parameters having a univariable logical regression P<0.2 yielded the combination of Ki and 
k4 as the most sensitive model (P<0.001) that distinguished tumour to benign tissue - 
sensitivity 84.2%, specificity 94.7%, PPV 94.1%, NPV 85.7%, and AUC 0.93. A 
representative case of [18F]DCFPyL SUV, Ki and k4 parametric maps is shown in Fig. 4.5. 
 
90 
 
 
Figure 4.5: Axial CT image (a), axial [18F]DCFPyL SUV map (range: 0 – 10.0 g/mL) 
superimposed on CT (b), coronal [18F]DCFPyL PET (range: 0 – 10.0 g/mL) (c), Ki 
parametric map (d), k4 parametric map (e) and localized tumour in red using the classifier 
from logistic regression (f), in a 64-year-old man with PCa (Gleason score 7 (3+4)). Pre-
op PSA was 8.17 ng/mL. Mean SUV of the tumour ROI was 13.4 g/mL. 
Abbreviations: CT = Computed tomography; DCFPyL = 2-(3-{1-carboxy-5-[(6-
[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid; SUV = 
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standardized uptake value; PET = Positron emission tomography; Ki = Net uptake rate 
constant from plasma; k4 = Dissociation rate constant; PCa = Prostate cancer; PSA = 
Prostate specific antigen; ROI = Region of interest. 
 
 Kinetic Parameters of [18F]FCH vs [18F]DCFPyL 
The in-vivo behaviour of [18F]FCH in 23 patients and [18F]DCFPyL in 19 patients were 
compared using kinetic parameters estimated from dynamic PET (see Fig. 4.4). There were 
no significant differences in K1 and k2 between the two tracers in both tumour and benign 
tissue. For [18F]FCH vs [18F]DCFPyL (mean ± SD) in tumour tissue, there was significant 
difference in SUV (3.98 ± 1.08 vs. 4.12 ± 3.64 ; P=0.01), k3 (2.91 ± 2.03 vs. 0.44 ± 1.04 
min-1; P=0.001), k4 (2.16 ± 2.13 vs. 0.08 ± 0.07 min
-1; P<0.001), Ki (0.20 ± 0.14 vs. 0.10 
± 0.10 mL/min/g; P=0.002) and DV (4.50 ± 3.83 vs. 3.40 ± 2.26 mL/g; P=0.03). In benign 
tissue, there was significant difference in SUV (2.66 ± 0.81 vs. 1.92 ± 0.37 g/mL; P=0.001), 
k3 (2.63 ± 2.06 vs. 0.51 ± 1.16 min
-1; P<0.001), k4 (1.75 ± 2.03 vs. 0.13 ± 0.12 min
-1; 
P=0.004), Ki (0.14 ± 0.07 vs. 0.05 ± 0.04 mL/min/g; P<0.001) and DV (3.01 ± 2.12 vs. 
1.50 ± 0.55 mL/g; P=0.001). Fig. 4.6 shows the normalized washout rate constant (k4/k3) 
of [18F]FCH and [18F]DCFPyL in DIL and benign tissue. This washout constant or inverse 
of binding potential was 1.86-fold higher in benign tissue than tumour for [18F]DCFPyL 
(P<0.05); however, for [18F]FCH, it was similar for both tissue types. In addition, for 
benign tissue, the normalized washout constant was higher for [18F]DCFPyL. 
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Figure 4.6: Comparison of normalized washout rate constant (k4/k3) (mean  SEM) of 
[18F]FCH and [18F]DCFPyL in both tumour and benign tissues, significant differences are 
marked with (*), P<0.05.  
Abbreviations: k4/k3 = Normalized washout rate constant (inverse of binding potential); 
SEM = standard error of the mean; FCH = Flourocholine; DCFPyL = 2-(3-{1-carboxy-5-
[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid. 
 
4.4 Discussion 
In this study, we estimated the F2TCM parameters of [18F]FCH and [18F]DCFPyL from 
dynamic PET studies of PCa patients and investigated whether these kinetic parameters 
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can differentiate DIL from benign tissue and explain the different SUV image 
characteristics observed with the two tracers. 
Logistic regression with backward elimination of variables showed that the combination 
of Ki and k4 and SUV alone were sensitive models for localizing and differentiating tumour 
from benign prostatic tissue with [18F]DCFPyL and [18F]FCH, respectively. The former 
tracer was more accurate according to AUC (0.93 vs 0.88; P<0.001 for both). Previous 
experience with [18F]FCH illustrated that it is challenging to localize the DIL without the 
prostate biopsy report because the tracer is not highly specific to PCa [10,11,21,22]. 
However, in selected patients who have undergone multiple TRUS-guided biopsies with 
negative findings, [18F]FCH SUV map could be helpful and contribute valuable additional 
information for detection of the primary tumour [11]. 
For [18F]DCFPyL, Ki and k4 were more sensitive than the semi-quantitative SUV used 
routinely in the clinic. Previous studies had demonstrated that optimal image qualities 
(SUV tumour to background ratio) was achievable at 60-120 mins post-injection [16,17] 
due to reduction in nonspecific background [23,24]. However, in this study, a 22-min 
dynamic PET acquisition with kinetic analysis to derive Ki and k4 of the F2TCM was able 
to differentiate tumour from benign tissue. Therefore, use of dynamic [18F]DCFPyL 
imaging may improve the efficiency of DIL imaging with PET by eliminating the 1-2 hr 
wait time between injection and SUV imaging. 
The observed better contrast between DIL and benign tissue with [18F]DCFPyL than 
[18F]FCH and that this contrast has been reported to increase with time[16,17] could be 
explained by the different kinetic behavior of the two tracers. Median k3, k4, Ki and SUV 
values of [18F]DCFPyL were smaller than those of [18F]FCH for both tumour and benign 
tissue. These differences in kinetics could explain why with [18F]FCH imaging can start 
soon after the tracer injection because [18F]FCH bound and dissociated more quickly than 
[18F]DCFPyL [10,12-14,25]. Higher normalized washout rate constant (k4/k3) indicates 
rapid washout relative to binding in the tissue. Fig. 4.6 shows that for [18F]DCFPyL, 
normalized washout rate constant was significantly higher in benign tissue than tumour 
(P<0.05) while for [18F]FCH, this rate constant was not significantly different. Therefore, 
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the contrast between tumour (DIL) and benign tissue would increase over time with 
[18F]DCFPyL while the same contrast would not change over time with [18F]FCH. Taken 
together, the kinetic analysis suggests that with [18F]FCH, SUV imaging can be done soon 
after injection but contrast between tumour and benign tissue does not improved over time. 
In contrast, with [18F]DCFPyL, to optimize contrast between tumour and benign tissue, 
SUV imaging has to be delayed, as literature suggested, to 1-2 hr post injection. However, 
with kinetic analysis of dynamic [18F]DCFPyL, the imaging time can be shortened to 22-
min post injection and the combination of Ki and k4 could identify DIL with high accuracy 
(AUC = 0.93). 
There are limitations with our study. First, dynamic [18F]DCFPyL imaging was limited to 
22-minute which precluded comparison with SUV at 1-2 h post injection for separating 
tumour (DIL) from benign tissue. Second, burden of disease on sextant biopsy was used 
for defining DIL locations and this may be subject to sampling error. Third, ideally the 
performance of [18F]FCH and [18F]DCFPyL would be compared in the same patient group 
but availability of the tracer (and concerns about cumulative radiation dose) precluded such 
a comparison. The two patient cohorts were accrued sequentially on the same research 
protocol (same eligibility) and both cohorts had similar clinical characteristics (Table 4.1) 
reducing possible bias. [24,26]. 
4.5 Conclusions 
Patients with PCa were studied with dynamic [18F]FCH PET and dynamic [18F]DCFPyL 
PET over a short acquisition time of 22-min. Multiple kinetic parameters were derived with 
the custom developed F2TCM from the dynamic studies and compared for distinguishing 
tumour from benign tissue. Among all the [18F]FCH PET and [18F]DCFPyL parameters 
investigated, the logistic regression model based on Ki (net uptake rate constant from 
plasma) and k4 (dissociation rate constant from binding) of [
18F]DCFPyL was the most 
accurate in identifying DIL containing sextants on prostate biopsy and these findings 
support the incorporation of dynamic imaging sequences into PET/CT protocols using 
[18F]DCFPyL. 
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Chapter 5  
5 Validating Dynamic [18F]DCFPyL PET and CT Perfusion 
Imaging Against Digital Histopathology for Detection 
and Localization of Dominant Intraprostatic Lesions in 
Prostate Cancer 
The contents of this chapter were previously submitted in the Journal of Nuclear Medicine 
by Dae-Myoung Yang, Ryan Alfano, Glenn Bauman, Joseph Chin, Stephen Pautler, 
Madeleine Moussa, Jose A. Gomez, Irina Rachinsky, Mena Gaed, Kevin J. Chung, John 
Valliant, Aaron Ward and Ting-Yim Lee. 
5.1 Introduction 
Prostate cancer (PCa) is a multi-focal disease. The most prominent cancerous lesion that is 
the largest in size within the prostate is called the dominant intraprostatic lesion (DIL). 
Identifying DIL is clinically important because it showed a strong correlation with prostate-
specific antigen (PSA) level and biochemical relapse [1,2]. Also, DIL is often the site of 
local recurrence post-treatment and from where metastases originate [3,4]. Conventional 
radiation therapy treats PCa by delivering a homogeneous dose to the entire gland. Multiple 
randomized studies have shown that dose-escalation or dose-boosting to DIL improves 
treatment outcomes in terms of biochemical recurrence-free survival [4-6]. Therefore, 
detecting and locating DIL is crucial for the control of PCa. In this study, we used dynamic 
positron emission tomography (PET) with the fluorine-18 labelled prostate-specific 
membrane antigen (PSMA)-ligand ([18F]DCFPyL) and CT Perfusion (CTP) to detect and 
localize DIL. The imaging techniques give complementary molecular (PET) and 
hemodynamic (CTP) information on PCa and normal prostate tissue. Therefore, the 
primary goal of this study is to determine if combining dynamic PET and CTP would better 
localize DIL than either imaging modality alone. Since dynamic PET is more expensive 
and requires more time to perform than CTP, a secondary goal is to compare the 
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performance of dynamic [18F]DCFPyL PET vs CTP in localizing DIL to inform the cost-
effectiveness of the two techniques. 
5.2 Methods 
 Study Design 
This prospective clinical study was approved by the Institutional Research Ethics Board. 
All participants in this study provided written informed consent. Subjects who had 
untreated biopsy-proven localized PCa were prospectively enrolled in this study. Inclusion 
criteria were as follows: aged 18 years or older; biopsy confirmed PCa; suitable for and 
consenting to radical prostatectomy for treatment. Subjects who had any of the following 
criterion were excluded from the study: prior therapy including hormone therapy for PCa, 
use of 5-alpha reductase inhibitors − finasteride or dutasteride − within 6 months of study 
date; unable to comply with all pre-operative imaging; prostate size exceeding the 
dimensions of whole-mount pathology slides; allergy to contrast agents used in CTP study; 
Sickle cell disease or other anemias; Impaired renal function (estimated GFR < 60 
mL/min/1.73m2); residual bladder volume > 150 cc (determined by post-void ultrasound); 
hip prosthesis and/or vascular graft that are MRI incompatible or other metallic objects 
within the pelvis; contraindication to MRI, such as a pacemaker or other electronic 
implants, known metal in orbit and cerebral aneurysm clips. The last two exclusion criteria 
were required because MRI was included in the research protocol; however, only ex-vivo 
MRI data of the explanted prostate was used for registration purpose and in-vivo MRI of 
the prostate was not included in the analysis of this study. 
 Dynamic [18F]DCFPyL PET Imaging 
Dynamic [18F]DCFPyL PET imaging was performed on a Discovery VCT (GE Healthcare, 
Waukesha, WI, USA) PET/CT scanner. A CT scan was taken with patients lying supine 
on the patient couch for localization of the prostate and attenuation correction of PET 
images. The dynamic [18F]DCFPyL PET scan covered the whole prostate and iliac arteries, 
the latter for acquiring the image-derived arterial time-activity curve required for kinetic 
analysis of dynamic PET data to generate parametric maps. Starting at the injection of 325 
101 
 
MBq of [18F]DCFPyL as a bolus into an antecubital vein, the dynamic PET scan acquired 
over 22 minutes the following number of volumes at each of seven framing intervals: 10 
at 10 s, 5 at 20 s, 4 at 40 s, 4 at 60 s and 4 at 180 s. Each volume comprised of forty-seven 
3.27 mm thick slices. Standardized uptake value (SUV) in g/mL was measured on the 
average of the last four dynamic PET volumes (10-22 min post-injection). 
The acquired dynamic volumes were analyzed to generate parametric maps of the whole 
prostate. We calculated influx rate constant (K1) in mL/min/g, efflux rate constant (k2) in 
min-1, binding rate constant (k3) in min
-1, dissociation rate constant (k4) in min
-1, net uptake 
rate constant from plasma (Ki) in mL/min/g and distribution volume (DV) in g/mL maps 
by deconvolving the arterial time-activity curve from tissue time-activity curve using a 
previously published flow-modified 2-tissue compartment model [7]. The image-derived 
arterial time-activity curve was obtained from a region inside an iliac artery. The tissue 
time-activity curve of each voxel was smoothed by a 3-by-3 mean filter with those from 
the immediate neighbouring pixels in the same slice. 
 CT Perfusion (CTP) Imaging 
Free-breathing CTP scan was performed immediately after the dynamic PET scan without 
moving the patient. The CTP Images were acquired over 3 min using a shuttle mode where 
two contiguous 4 cm sections of the pelvis covering the prostate and both iliac arteries, 
identified from the CT localization and attenuation correction scan, were alternately 
scanned starting 6 seconds after a bolus injection of contrast agent (Isovue 370, Bracco 
Diagnostic Inc., NJ, USA) at a rate of 3 ml/s and a dosage of 0.7 ml/kg into an antecubital 
vein. The CTP images were acquired using 5 mm thick slices, 120 kVp and 50 mAs in two 
phases: the first phase, at intervals of 2.8 s for first 1 min; the second phase, every 15 s for 
the next 2 min. 
The acquired dynamic CT volumes were co-registered using non-rigid image registration 
(GE healthcare) to minimize misregistration from breathing motion before functional 
maps, including blood flow (BF) in mL/min/100g, blood volume (BV) in mL/100g, mean 
transit time (MTT) in second, vessel permeability surface product (PS) in mL/min/100g 
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and contrast delay time (T0) in second, were generated with CT Perfusion (GE Healthcare) 
software. 
 Image Registration and Analysis 
After surgical resection in the operating room, the prostate specimen was placed in 10% 
buffered formalin and marked with fiducial markers [8]. The specimen was then 
temporarily placed in a Christo-Lube (Lubrication Technology, Franklin Furnace, OH, 
USA) filled container for imaging with MRI including T2-weighted that was used for 
registration as described below. MR images were was performed on a Discovery MR750 
(GE Healthcare, Waukesha, WI, USA) at 3T. Christo-Lube was used to provide a black 
background and minimize boundary artifacts in the MR images. After fixing in formalin 
for 48 hours, the specimen was processed as per the standard pathology grossing protocol 
and submitted for routine processing, paraffin embedding, and reporting. Whole-mount 4 
μm-thick hematoxylin and eosin (H&E)-stained histology cross sections spanning the 
entire mid prostate were then digitized for contouring. 
In order to correlate the pre-operative PET and CTP parametric maps to cancerous nodules 
identified in digital histopathology images of the explanted prostate, a registration pipeline 
was developed, as shown in Fig. 1. The ex-vivo T2w MRI was used as the bridge to co-
register ex-vivo histopathology images to PET/CTP parametric maps. Ex-vivo MR-
histology registration was done using fiducial markers [8]. Co-registration of CTP average 
map and ex-vivo T2w-MRI was done manually with ITK-SNAP (www.itk-snap.org) using 
the shape of and anatomical landmarks in the excised prostate gland [9]. PET-CTP co-
registration was achieved by registering the CT images acquired for attenuation correction 
of dynamic PET and CTP average maps with the automated 3D registration module − 
General Registration − in 3D slicer (www.slicer.org) [10]. After co-registration of PET and 
CTP parametric maps with histopathology images, regions of interest were drawn on the 
latter images, to encompass the DIL and the entire prostate outside the DIL by pathologists 
(contoured by MG and verified by MM and JAG (pathologists)). The DIL was identified 
as largest cancerous lesion in size within the histopathology images. These ROIs were 
superimposed on PET and CT parametric maps to generate voxel and volumetric data for 
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DIL and non-DIL prostatic tissue. There were 51,585 voxels in DIL and non-DIL ROIs. 
For volumetric analysis, ROIs from all slices were combined into their respective volume 
of interest (VOI) to calculate the mean value of each parameter in DIL and non-DIL VOI. 
 
 
Figure 5.1: Registration Pipeline. 
Abbreviations: CT = Computed tomography; T2w = Transverse relaxation time 
weighted; MR = Magnetic resonance; BF = Blood flow; BV = Blood volume; MTT = 
Mean transit time; PS = Vessel permeability surface product; To = Contrast delay time; 
K1 = Influx rate constant; k2 = Efflux rate constant; k3 = Binding rate constant; k4 = 
Dissociation rate constant; Ki = Net uptake rate constant; DV = Distribution volume; 
SUV = Standardized uptake value. 
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 Statistical Analysis 
Statistical analyses were performed in SPSS Statistics 26 (IBM Analytics, Armonk NY), 
using two-sided statistical testing with significance accepted at P < 0.05. Descriptive 
statistics were presented as mean and SD or as median and range (min to max). Differences 
between DIL and non-DIL imaging parameters were compared using the Wilcoxon signed-
rank test for volumetric analysis and the Mann-Whitney U test for voxel-wise analysis. 
Multivariable linear logistic regression with backward elimination was used to determine 
the most accurate model of [18F]DCFPyL PET and CTP parameters from a subset, each of 
which attained P < 0.2 in univariable testing, to distinguish DIL from non-DIL tissue. We 
performed leave-one-patient-out cross-validation to validate the selected model from 
logistic regression for voxel-wise analysis and reported the average and standard deviation 
of error rate (ER), false positive rate (FPR) and false negative rate (FNR), area under the 
receiver operating characteristic curve (AUC), sensitivity and specificity of all folds as the 
results. 
5.3 Results 
 Patients 
15 patients (median age, 63 yr; range, 53–68 yr) were included in this study. The detailed 
clinical-pathological characteristics of patients are listed in Table 1.  
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Table 5.1: Clinical–pathological characteristics of patients and tumours (n = 15) 
Age [y] 62.1 ± 4.1 (53-68)* 
Weight [kg] 88.8 ± 11.4 (65-109)* 
Height [cm] 177.4 ± 6.1 (170-191)* 
PSA [ng/mL] 9.4 ± 6.3 (3.5-25.5)* 
Injected [18F]DCFPyL Activity [MBq] 312.4 ± 15.9 (280.8-348.2)* 
Histology – n(%) 
Adenocarcinoma 15 (100) 
pT Stage – n(%) 
T2c 7 (46.7) 
T3a 7 (46.7) 
T3b 1 (6.7) 
pN Stage – n(%)   
N0 15 (100) 
N1 0 (0) 
NX 0 (0) 
pM Stage – n(%)   
M0 15 (100) 
M1 0 (0) 
MX 0 (0) 
Gleason score of DIL – n(%) 
6 (3+3) 1 (6.7) 
7 (3+4) 6 (40.0) 
7 (4+3) 5 (33.3) 
9 (5+4) 3 (20.0) 
Note. Data are the number of patients with the percentage in parentheses unless otherwise 
indicated. 
* Data are means ± standard deviation, with the range in parentheses. 
Abbreviations: DCFPyL = 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-
amino]-pentyl}-ureido)-pentanedioic acid; PSA = Prostate specific antigen; pT = Primary 
tumour; pN = Lymph node; pM = Distant metastasis; DIL = Dominant intraprostatic 
lesion. 
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 Descriptive Statistics and Parameter Selection 
There were 12 parametric maps generated from dynamic [18F]DCFPyL PET and CTP. Fig. 
2 shows all the PET and CT parametric maps co-registered to the digital histopathology 
images for one of the patients. Univariable logistic regression analysis at VOI level 
revealed that the following [18F]DCFPyL PET and CTP parameters distinguished DIL vs. 
non-DIL tissue with statistical significance − BF (median 61.23 vs. 44.05 mL/min/100g, 
P<0.001), BV (median 8.95 vs. 6.35 mL/100g, P<0.001), PS (median 28.87 vs. 20.11 
mL/min/100g, P<0.001), K1 (median 0.257 vs 0.153 mL/min/g, P<0.001), k2 (median 
0.326 vs. 0.270 min-1, P<0.05), k4 (median 0.089 vs. 0.108 min
-1, P<0.05), Ki (median 
0.076 vs. 0.027 mL/min/g, P<0.001), DV (median 2.73 vs. 1.17 mL/g, P<0.001) and SUV 
(median 3.02 vs. 1.87 g/mL, P<0.001). Amongst these parameters, logistic regression with 
backward elimination revealed Ki and k4 was the most accurate and significant model 
(P<0.001) to separate DIL from non-DIL tissue with 100% sensitivity and specificity and 
AUC of 100% (95% CI, 100-100%). Among CTP parameters, BF and MTT model 
(P<0.001) was the most accurate model to distinguish DIL from non-DIL tissue with AUC 
of 92.4% (95% CI, 82.3-100%), sensitivity 86.7%, specificity 86.7%, positive predictive 
value (PPV) 86.7% and negative predictive value (NPV) 86.7%. As a comparison, SUV 
reached AUC of 95.1% (95% CI, 88.2-100%), sensitivity 86.7%, specificity 86.7%, PPV 
86.7% and NPV 86.7%. 
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Figure 5.2: Examples of co-registered CTP and [18F]DCFPyL parametric maps to 
histopathology from a patient. The location of DIL is outlined in black in histology. 
Abbreviations: CT = Computed tomography; T2 = Transverse relaxation time; MR = 
Magnetic resonance; BF = Blood flow; BV = Blood volume; MTT = Mean transit time; 
PS = Vessel permeability surface product; To = Contrast delay time; K1 = Influx rate 
constant; k2 = Efflux rate constant; k3 = Binding rate constant; k4 = Dissociation rate 
constant; Ki = Net uptake rate constant; DV = Distribution volume; SUV = Standardized 
uptake value. 
 
In voxel-wise analysis, a total of 51585 voxels were extracted from the both DIL and non-
DIL VOIs of all patients. The following [18F]DCFPyL PET and CTP parameters showed 
significant differences to distinguish DIL vs. non-DIL voxels with univariable logistic 
regression analysis : BF (64.83 ± 25.06 vs. 45.66 ± 22.36 mL/min/100g, P<0.001), BV 
(9.54 ± 4.24 vs. 6.01 ± 3.31 mL/100g, P<0.001), MTT (14.20 ± 6.54 vs. 12.53 ± 6.42 s, 
P<0.001), PS (29.02 ± 14.18 vs. 18.58 ± 11.27, P<0.001), T0 (10.63 ± 4.67 vs. 10.26 ± 
4.57 s, P<0.001), K1 (0.300 ± 0.107 vs. 0.157 ± 0.077 mL/min/g, P<0.001), k2 (0.386 ± 
0.241 vs. 0.296 ± 0.191 min-1, P<0.001), k3 (0.248 ± 0.238 vs. 0.197 ± 0.232 min
-1, 
P<0.001), k4 (0.099 ± 0.066 vs. 0.114 ± 0.097 min
-1, P<0.001), Ki (0.08 ± 0.04 vs. 0.03 ± 
0.02 mL/min/g, P<0.001), DV (3.01 ± 1.65 vs. 1.34 ± 0.85 mL/g, P<0.001) and SUV (4.06 
± 2.18 vs. 1.76 ± 0.60 g/mL, P<0.001). Among these statistically significant [18F]DCFPyL 
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PET and CTP parameters, the combination of Ki and k4 was again the most accurate model 
to distinguish DIL from non-DIL voxel using multivariable logistic regression with 
backward elimination (P<0.001). If only significant CTP parameters were used, the BF and 
MTT model was the most accurate model (P<0.001). 
 Cross-Validation and Diagnostic Performance 
Three DIL detection models for voxel-wise analysis − KI and k4; BF and MTT; and SUV 
− were validated using leave-one-patient-out cross-validation. The ER, FPR, FNR and 
AUC obtained for each model are shown in Fig. 3. KI and k4 was the most accurate and 
stable model to detect DIL. It had ER of 7.9 ± 7.3%, FPR of 7.7 ± 8.5% and FNR of 5.5 ± 
8.5% and the AUC of 95.7 ± 0.6%. BF and MTT model showed ER, FPR, FNR and AUC 
of 32.3 ± 11.6%, 31.6 ± 15.3% and 33.1 ± 21.7%, 76.5 ± 0.9% respectively while for SUV, 
ER, FPR, FNR and AUC of 11.3 ± 15.2%, 9.9 ± 16.6%, 32.0 ± 33.9%, 89.1 ± 0.8% 
respectively. 
 
 
Figure 5.3: Comparison of leave-one-patient-out cross-validation metrics of the different 
DIL detection models for voxel-wise analysis − error rate (ER), false positive rate (FPR), 
false negative rate (FNR) and AUC.  
Abbreviations: Ki = Net uptake rate constant; k4 = Dissociation rate constant; SUV = 
Standardized uptake value; BF = Blood flow; MTT = Mean transit time; ER = error rate; 
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FPR = False positive rate; FNR = False negative rate; AUC = Area under the curve of 
receiver operating characteristic curve; DIL = Dominant intraprostatic lesion. 
 
Dice similarity coefficient which gauged the similarity in size and location between the 
DIL detected by each model against that delineated by pathologists (MM,MG) on the 
digital histopathology images was 0.81 ± 0.18, 0.39 ± 0.21 and 0.63 ± 0.34, respectively 
for Ki and k4 model, BF and MTT model and SUV. 
5.4 Discussion 
In this study, we investigated using dynamic [18F]DCFPyL PET kinetic parameters and 
CTP parameters to detect and localize DIL in 15 newly diagnosed intermediate to high risk 
PCa patients and validated the developed method against digital histopathology images. 
Our analysis showed that compared to SUV and CTP parameters, the Ki (net uptake rate 
constant of [18F]DCFPyL from plasma) and k4 (dissociation rate constant of [
18F]DCFPyL 
after binding to PSMA on PCa cells) model was the most accurate and stable model to 
detect and localize DIL with excellent diagnostic performance as validated using leave-
one-patient-out cross-validation (Fig. 3). These results demonstrated the advantage of 
kinetic analysis of dynamic [18F]DCFPyL PET over SUV in detecting DIL in PCa. 
SUV obtained from a single static image at a fixed time after injection cannot differentiate 
the different processes of the tracer uptake including: tracer delivery via blood flow, 
bidirectional exchange between vessels and tissue, and binding to and dissociation from 
the target. As such, the optimal imaging time to achieve high SUV in tumour and high 
tumour-to-background contrast may vary between patients because of the interpatient 
variability and intrapatient heterogeneity of PCa [11]. On the other hand, the flow-modified 
2-tissue compartment model used in the kinetic analysis of dynamic [18F]DCFPyL was able 
to separate the different uptake processes in terms of the kinetic parameters and hence 
provide a better description of the different tracer kinetics in DIL vs non-DIL tissue. This 
difference could explain the better performance of [18F]DCFPyL kinetic parameters 
relative to SUV in detecting DIL. Among 15 patients in this study, DIL could not be 
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detected and localized in 3 patients using SUV. Fig. 4 showed a patient example where the 
Ki and k4 model can but SUV cannot detect and localize the DIL. This agrees with literature 
recommendation that if SUV is used to detect PCa, the imaging has to be performed at > 1 
h post-injection [12,13] while in this study the SUV map was acquired at 10-22 min post-
injection. It is noteworthy that the linear classifier from the Ki and k4 model shows that DIL 
had high net uptake rate constant (Ki) and low dissociation rate constant from PSMA once 
bound (k4). This would suggest that even with favorable kinetics, SUV acquired at short 
time post-injection cannot reliably differentiate DIL from non-DIL tissue. In comparison, 
our short 22 min dynamic [18F]DCFPyL study can determine Ki and k4 reliably to detect 
DIL more accurately than SUV. This has important clinical implications in patient 
throughput and scheduling. 
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Figure 5.4: Comparing DIL detection using Ki and k4 model vs SUV in a patient. The 
location of DIL is outlined in white in CT, SUV, Ki, k4 and DIL map and black in 
histology. 
Abbreviations: CT = Computed tomography; SUV = Standardized uptake value; Ki = Net 
uptake rate constant; k4 = Dissociation rate constant; DIL = Dominant intraprostatic 
lesion. 
 
Diagnostic performance differed between volumetric and voxel-wise analysis with the 
former analysis showing better results. While the BF and MTT model showed AUC of 
92.4% and 76.5% in volumetric and voxel-wise analysis, the AUC for the Ki and k4 model 
changed from 100% to 95.7%, respectively. The AUC (and other performance metric) 
decrease was due to higher noise in the voxel vs volumetric data. Besides noise, the 
different effect size (signal strength) can also explain the different decrease in performance 
metrics of different models in moving from volumetric to voxel-wise analysis. For 
example, the difference between DIL and non-DIL in BF and MTT were 0.42- and 0.10-
fold, whereas Ki and k4 had a difference of 1.54- and 0.13-fold, respectively. BF and MTT 
had a smaller effect size because non-DIL includes secondary tumour nodule and benign 
prostatic hyperplasia; the latter is known to have high blood flow and blood volume. [14] 
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In contrast to non-specific CT contrast agent, [18F]DCFPyL targets the specific expression 
of PSMA of PCa which region exhibits 100- to 1000-fold overexpression than benign 
prostatic tissue [15]. 
For voxel-wise analysis, BF and MTT model from CTP showed sensitivity and specificity 
of 66.9% (FNR 33.1%) and 68.4% (FPR 31.6%), respectively, which were lower than the 
other two models based on [18F]DCFPyL. Nevertheless, these results were still comparable 
to the sensitivity and specificity of multi-parametric MR (mp-MRI) which ranged from 54-
87% and 74-100%, respectively [16]. Furthermore, an important advantage of CT 
Perfusion is that it can be easily incorporated into current clinical CT scanning protocols 
used in the diagnosis of cancer and follow-up of treatment by adding only a couple of 
minutes in scanning time and being less expensive than either mp-MRI or PET. 
Additionally, such functional CT imaging lends itself to integration with existing CT 
planning processes for radiation treatment, potentially enabling differential tumor volume 
boosting [17]. 
This study has several limitations. First, the number of enrolled patients in this study was 
relatively small. The results obtained have to be interpreted with caution but warrant 
confirmation with another study with a larger number of patients. Second, [18F]DCFPyL 
SUV was acquired at 10-20 min post-injection. It is not known if the performance of a later 
SUV would be equivalent to that of the Ki and k4 model in detecting DIL vs non-DIL. Even 
if that was the case, a 1-2 h delay scan would have presented more logistics problem than 
our 22-min dynamic PET stud. Third, we used binomial logistic regression limiting our 
detection method to two tissue types − DIL and non-DIL. A trinomial logistic regression 
would allow separate of three tissue types – DIL, non-DIL cancer nodules and normal 
prostatic tissue. The small number of patients available precluded a reliable investigation 
of this possibility. Moreover, if the clinical goal is to identify DIL for boosting the radiation 
dose, a two tissue type separation method would be sufficient for this purpose. 
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5.5 Conclusion 
Kinetic analysis of dynamic [18F]DCFPyL PET yielded the net uptake rate constant of 
[18F]DCFPyL from plasma (Ki) and its dissociation rate constant after binding (k4) to 
PSMA as a more accurate and reliable model to detect DIL than simple SUV. Moreover 
the model detected DIL overlapped >80% with that delineated by pathologist based on 
histopathology of excised prostate sections. 
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Chapter 6  
6 Conclusions and Future Works 
The final chapter of this dissertation provides a summary of the main findings and 
conclusions of Chapters 2 to 5. This chapter will also present future applications and 
directions for using quantitative dynamic PET/CT techniques with the F2TCM. 
6.1 Summary and Conclusions 
This Ph.D. researches focused on developing quantitative hybrid PET/CT for monitoring 
treatment response and diagnosis of cancer. Dynamic [18F]FDG and CTP were used to 
monitor the response of NSCLC to stereotactic body radiotherapy (SABR). Contrary to the 
current understanding that [18F]FDG becomes trapped in cells as [18F]FDG-6-P after 
phosphorylation by hexokinase, the reversibility of the trapping was discovered, as shown 
in Chapter 2. The reversible binding is due to the activity of glucose-6-phosphate 
dehydrogenase (G6PD), which shunts [18F]FDG-6-P into the pentose phosphate pathway. 
G6PD is involved in the protective response mechanism against an elevated level of 
oxygen-free radicals [1,2]. Therefore, this G6PD activity may have treatment implications; 
for example, the hyperactive G6PD may imply efficacy of radiation treatment, which 
depends on the generation of oxygen free radicals. 
The imaging parameters from dynamic [18F]FDG and CTP were compared to the treatment 
response after SABR in terms of pathological complete response (pCR) to evaluate whether 
these imaging parameters could monitor/predict the treatment response in Chapter 3. Blood 
volume pre-SABR treatment (BVpre-SABR) and relative change in SUVmax from before to 
after treatment (SUVmax) were able to predict the treatment outcome within 8 weeks of 
treatment. The area under curve (AUC) of the receiver operating characteristics (ROC) 
curve for monitoring treatment response using BVpre-SABR and SUVmax was 0.92. With 
RECIST and PERCIST, the AUC was 0.54 and 0.58, respectively. The results 
demonstrated that dynamic [18F]FDG and CTP were better than size measurement for 
RECIST and tracer uptake for PERCIST in predicting the treatment response after SABR. 
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In chapter 4, I applied the flow-modified 2 tissue compartment model (F2TCM), co-
developed with another PhD student, to understand the different kinetic behaviour of two 
targeted PET tracers for prostate cancer (PCa), [18F]FCH and [18F]DCFPyL. The uptake 
rate and binding rate constant of [18F]FCH were over 2-fold higher than [18F]DCFPyL. 
This finding explains why static SUV imaging to detect PCa with [18F]FCH requires shorter 
delay imaging time (within 30-min) than [18F]DCFPyL (over 2-hr). Furthermore, [18F]FCH 
tumour contrast relative to blood background remained the same over time post-
administration, whereas [18F]DCFPyL contrast increased over time. This difference in 
relative tumour contrast was explained by the normalized washout rate constant, the ratio 
of dissociation rate constant from target to binding rate constant to target. For [18F]FCH, 
the normalized washout rate constant did not differ between tumour and benign; hence the 
differential contrast between tumour and blood background remained the same over time. 
However, [18F]DCFPyL normalized washout rate constant was two times higher in 
background than tumour; therefore, the differential tumour contrast increased over time. 
The size and/or oncologic activity of the dominant intraprostatic lesion (DIL) have 
important prognostic implications for PCa. Twenty-two-min dynamic [18F]DCFPyL PET 
and CT Perfusion (CTP) study were used to determine which sets of kinetic parameters 
were able to differentiate DIL from non-DIL tissue defined by digital histopathology 
images of excised whole prostate gland from radical prostatectomy. A registration pipeline 
was developed based on 3D Slicer [3] and iTK-snap [4]. All corresponding PET and CT 
images were co-registered to the digital pathology images using a 3-step co-registration 
processes in sequence: digital histopathology with ex-vivo MR; ex-vivo MR with CTP 
average images; CT images from [18F]DCFPyL PET/CT with CTP average images. This 
registration process allowed DIL and non-DIL regions identified and drawn by pathologists 
to be superimposed on PET and CT images for volumetric analysis and allowed voxel-
based analysis to determine the optimal set of parameters to separate DIL from non-DIL. 
Logistic regression identified Ki (the net transfer rate constant) and k4 (the dissociation rate 
constant from target) as the optimal combination of parameters to separate DIL from non-
DIL in both volumetric and voxel-based analysis. Using leave-one-patient-out cross-
validation, the AUC of the ROC curve for detecting and localizing DIL using Ki and k4 was 
0.96. AUC with SUV alone was 0.89, and with BF and MTT from CTP was 0.77 similar 
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to multi-parametric MR [5]. These results demonstrate that a 22 minutes dynamic 
[18F]DCFPyL was better than a static SUV in detecting and localizing DIL. Also, given the 
better accessibility of CTP, it may be a cost-effective method for the same task. 
6.2 Future Directions 
 External Validation of Evaluation using Quantitative Hybrid 
PET/CT 
Functional parameters using quantitative hybrid PET/CT have shown the potential in the 
early assessment of response following SABR treatment for lung cancer and detecting DIL 
for prostate cancer. However, the findings in studies of this thesis may not be generalizable 
to the general clinical population due to their limited sample size. Further validation with 
large sample size and preferable multi-center studies is required. 
 Treatment Planning for Radiation Therapy 
Radiation therapy is a treatment option for localized prostate cancer. Irradiating prostate 
with focal dose escalation to DIL, where DIL receives much higher radiation dose than the 
whole prostate (5-23% higher dose), is a new emerging treatment technique [6,7]. The 
recurrence of prostate cancer occurred frequently at the site of DIL and escalated radiation 
treatment to the DIL was associated with improved treatment outcome. Hence, the exact 
delineation of DIL is crucial for focal dose escalation radiation therapy. 
Studies in this thesis showed that the kinetic parametric maps from dynamic [18F]DCFPyL 
PET achieved an AUC of 0.96 in detecting and localizing DIL. In comparison, AUC of 
detecting and localizing DIL with SUV of PSMA-PET and multiparametric MRI were 0.91 
and 0.79, respectively [8]. Therefore, the potential to improve treatment outcome by using 
kinetic parametric maps from dynamic [18F]DCFPyL PET to accurately delineate DIL and 
guide focal dose escalation could be a worthwhile follow-up study. 
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 Personalized Targeted Radionuclide Therapy 
Targeted radionuclide therapy is a new form of radiation therapy for advanced cancers [9-
12]. The cell-targeting molecule/vehicle (e.g. antibodies, peptides, small molecules and 
etc.) is labelled with therapeutic radionuclides like 177Lu and 225Ac which unlike diagnostic 
18F or 68Ga can deposit a substantial radiation dose directly to tumour cells thereby killing 
them with their high energy but short range particle radiation but spare the neighbouring 
normal cells. For example, [225Ac]PSMA-617 targets and destroys metastatic prostate 
cancer with a high expression of PSMA by the emitted alpha particles. 
Calculation of internal radiation dose from targeted radionuclide therapy requires 
knowledge of the area under the time activity curve (TAC) of the administered targeted 
radionuclide in the tumour and critical organs − kidneys, lungs, bone marrow, bladder and 
others. These TACs are usually obtained by measuring the targeted radionuclide 
distribution in the whole body over time in a small sample of patients and averaged. These 
‘population averaged’ TACs are then applied to calculate the radiation dose to tumour and 
critical organs in individual patients. Because of intersubject differences in 
metabolism/catabolism of the targeted radionuclide and tumour characteristics, the TACs 
in an individual patient could be very different from the ‘population average’ leading to 
either under- or over-dosing of tumour or toxicity from overdosing of critical organs. An 
example is a Phase III trial of peptide radionuclide therapy for neuroendocrine tumour 
where the toxicity was low but efficacy was moderate compared to conventional treatment 
[13]. In this trial the majority of patients could be undertreated because the prescribed 
targeted radionuclide dose was based on the ‘population average’ TAC. I propose using 
diagnostic tracer ([18F]DCFPyL or [68Ga]PSMA-11) and kinetic modelling for 
personalized treatment planning with therapeutic tracer ([177Lu]PSMA-617 or 
[225Ac]PSMA-617]). Kinetic parameters from a dynamic diagnostic tracer study can be 
used to predict the entire, for example >5 physical half-lives of the radionuclide, time-
activity curve of therapeutic tracer and dose delivered to each patient. This prediction 
method would allow radiation dose to be optimized for maximizing treatment efficacy and 
minimize toxicity. 
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